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The diverse microbial populations constituting the intestinal microbiota 
promote immune development, nutrient digestion and colonization resistance 
against invading pathogens. Due to their complex metabolic requirements and 
the consequent difficulty culturing them, they remained, until recently, largely 
uncharacterized. In the past decade, deep nucleic acid sequencing platforms, 
new computational and bioinformatics tools and full genome characterization 
of several hundred commensal bacterial species have facilitated studies of the 
microbiota and revealed that differences in microbiota composition can be 
associated with a myriad of conditions and that the microbiota can be 
manipulated to prevent, reduce and even cure some of them. One of the most 
critical functions of the microbiota is to prevent the expansion of disease-
causing organisms. Different bacterial species exert different roles within the 
intestine and therefore, the composition of the microbiota determines, in part, 
the level of resistance to infection. Perturbation of microbial communities with 
antibiotics renders the host susceptible to colonization by opportunistic 
antibiotic-resistant bacteria. The studies discussed in this dissertation aim to 
determine the impact that vancomycin-resistant Enterococcus (VRE) and 
carbapenem-resistant Klebsiella pneumoniae, two common hospital-acquired 
infections, have on each other and on the host and to identify intestinal 
bacteria responsible for colonization resistance against VRE. We demonstrate 
that VRE and K. pneumoniae coexist within the intestine despite residing in 
very close proximity to each other and that colonization resistance against 
VRE can be mediated by two bacterial species despite antibiotic treatment. 
This work highlights the complex interplay between gut bacteria and has 
important implications for the development of new therapeutics to treat 
intestinal infections.  
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CHAPTER 1 
 
INTRODUCTION 
 
1.1. OVERVIEW 
 
1.1.1. The gastrointestinal microbiota 
The development in metazoans of a tubular tract for food digestion, nutrient 
absorption and waste expulsion is believed to have occurred over 500 million 
years ago (1). The evolution of the intestinal tract created a niche for microbial 
symbionts, with resulting complex microbial populations that are uniquely 
adapted to life in this environment and that, to greater and lesser extents, 
depend upon each other for survival. Although these microbial populations 
have, for hundreds of years, provoked curiosity among microscopists, 
microbiologists and physiologists, they remained largely uncultured and 
therefore uncharacterized, in part because they generally do not cause 
disease. The last decade, however, has seen remarkable progress in our 
understanding of the mammalian intestinal microbiota and its impact on 
immune system development and function (2,3).  While much of the focus of 
microbiota and microbiome studies has been on microbiota composition of 
normal, healthy individuals (4-6), parallel studies have correlated microbiota 
composition with a wide range of diseases. The major messages emerging 
from this growing body of work are that healthy humans are colonized with 
diverse microbial populations that differ between individuals, that different 
microbes can have distinct interactions with the innate and adaptive immune 
systems of their mammalian host and that exogenous factors, in particular 
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medical interventions such as antibiotic administration, can lead to marked 
changes in the microbiota with downstream implications for health.   
 
1.1.2. Bioinformatic and computational platforms for microbiota / 
microbiome analysis 
Multi-parallel nucleic acid sequencing has greatly enhanced our understanding 
of commensal bacterial populations. Microbiota composition is generally 
determined by sequencing PCR-amplified bacterial 16S ribosomal RNA genes 
followed by analysis of sequencing data with bioinformatic programs such as 
Mothur (7) that assign taxonomic labels to each sequence. Other methods 
such as UniFrac enable investigators to compare complex samples and to 
correlate microbiota composition with specific experimental or clinical 
scenarios (8). Another method that has enabled investigators to identify 
bacterial taxa that differ between samples is LEfSe (linear discriminant 
analysis effect size), which supports high-dimensional class comparison 
between microbiomes obtained from different groups (for example colitis 
versus normal control samples (9).  Programs such as MetaPhlAn (9) facilitate 
the determination of bacterial taxon prevalence in samples that have been 
shotgun sequenced, while PICRUSt enables investigators to estimate the 
representation of microbial metabolic pathways on the basis of 16S rRNA 
taxonomy (10). These platforms are well established and are commonly used 
for microbiota and microbiome analyses. 
   More recently, mathematical models have been used to predict shifts in 
microbiota composition following different perturbations and to identify 
interactions between distinct bacterial taxa. Using modified Lotka-Voltera 
equations, which were originally derived to mathematically model predator-
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prey dynamics, a mathematical approach has been described that 
incorporates the growth rate of different bacterial taxa, their susceptibility to 
specific perturbations (such as antibiotic administration) and their impact on 
each other. If provided with quantitative data on the density of specific 
bacterial populations, and knowledge of their growth rate and susceptibility to 
a specific perturbation, one can calculate the strength of interactions between 
different bacterial populations (11).  Using this approach, a sub-network of 
bacterial groups was identified that appears to confer protection against 
Clostridium difficile infection. Another mathematical approach studying 
reconstitution of germ-free mice with complex flora suggested that interactions 
between bacterial species range from competitive to parasitic, with the 
surprising result that mutualistic interactions were not detectable (12).     
 
1.1.3. Microbiota composition and the intestinal environment 
Using these computational tools, we have come to learn that the composition 
and density of the microbiota varies along the gastrointestinal tract. The 
stomach, due to its highly acidic pH, harbors around 101-103 bacteria per gram 
of content and consists, for the most part, of organisms belonging to the 
Lactobacillus genus and in some instance, disease-causing organisms such 
as Helicobacter pylori (13). The small intestine is most densely colonized in 
the distal region, where nearly 108 bacteria per gram of content reside. Most 
bacteria found there belong to the Firmicutes and Bacteroidetes phyla, the two 
most dominant phyla in the gastrointestinal tract (GI), and include members of 
the Lactobacillaceae, Enterococcaceae, Erysipelotrichiaceae, Clostridiaceae, 
and Bacteroidaceae families (14,15). The large intestine is the most diverse 
and colonized compartment of the GI tract harboring bacterial levels in the 
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1010-1012 range. Similar to the small intestine, the large intestine is dominated 
by Firmicutes and Bacteroidetes. Other phyla, such as Proteobacteria, 
Verrucomicrobia and Actinobacteria are represented as well but in much lower 
frequencies (16). The majority of bacteria that make up the microbiota are 
strict anaerobes with complex nutritional requirements. Although rich in 
nutrients, the environment of the intestine is not uniform and just like the 
bacterial composition differs by compartment, so does the intestinal 
environment. For instance, pH and oxygen gradients vary along the GI tract, 
with the stomach being the most acidic and aerobic compartment while the 
colon is relatively neutral and anaerobic (16). Therefore, the low-acidity, low-
oxygen, high-nutrient environment of the large intestine explains the large 
bacterial density found at this site. Variation in microbiota composition within 
healthy human populations has led to the enterotype hypothesis, which posits 
that humans can be divided into three groups on the basis of their fecal 
microbiota composition (6). The fecal microbiota of healthy individuals could 
be grouped into three enterotypes, one predominated by Prevotella, a second 
by Bacteroides and the third by Ruminococcus.  
 
1.1.4. Bacterial interactions mediate the balance between health and 
disease 
Our understanding of how microbiota complexity is maintained and how the 
individual bacterial taxa compete with and support each other is rudimentary 
but important new insights have emerged. Metabolism of host-derived 
polysaccharides by Bacteroides fragilis, an obligately anaerobic bacterial 
species that inhabits the human colon, is required for intestinal colonization 
and persistence and genetic deletion of the polysaccharide utilization locus 
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markedly reduces competitiveness in the gut (17). Commensal microbiota-
mediated metabolism of host polysaccharides, for example the cleavage of 
sialic acid or fucose from host mucin, can promote infection with 
enterohaemorrhagic Escherichia coli, Salmonella typhimurium and Clostridium 
difficile by promoting virulence gene expression (18) or by enhancing growth  
(19).   
 The interactions between different bacterial taxa in the gut can be 
direct, i.e. resulting in the inhibition or support of bacterial species A by 
bacterial species B, or indirect, by modification of immunologic or physiologic 
host factors by bacterial species B which then either inhibit or support 
colonization by species A. Studies of these interactions are greatly facilitated 
by isolation, growth and characterization of the wide array of commensal 
bacterial species, a critical step that is both technically challenging and, given 
the marked genomic differences between bacterial strains belonging to the 
same species, daunting in terms of the massive number of potential strains to 
be studied. The importance of characterizing multiple strains was 
demonstrated in a study of four Bifidobacterium longum strains, of which only 
two provided resistance against an intestinal pathogen (20). Recent studies 
demonstrate that many colon-derived bacterial species can be cultured in vitro  
(21), including bacterial species that drive in vivo T cell differentiation (22,23). 
From an immunologic perspective, the impact of microbiota composition is 
increasingly recognized as important, with some bacterial taxa driving 
intestinal T-regulatory cells while others induce Th17 T cell development (22-
25). 
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1.2. INTESTINAL EPITHELIAL BARRIER AND INNATE IMMUNE 
DEFENSES 
 
1.2.1. Mucin and epithelial cell-mediated barriers of infection 
While blood draining the gut flows to the liver, which protects the systemic 
circulation by filtering microbes that traverse the intestinal epithelium (26), the 
most important barrier to bacterial entry of deeper tissues is the intestinal 
epithelium. The mucin layer that coats luminal epithelial cell surfaces 
physically excludes microbes inhabiting the intestinal lumen. Direct bacterial 
contact with luminal epithelial cell surfaces can occur in the absence of 
intestinal mucin layers or when specific microbes can penetrate mucin. The 
predominant mucin secreted by goblet cells is Muc2, which is a large, highly 
glycosylated multi-domain protein that forms di-sulfide bonded trimers that are 
partially resistant to trypsin. Muc2 forms a dense, approximately 50mm thick 
mucin layer in the colon that is attached to underlying epithelial cells and a 
more dispersed outer layer	   (27). Some pathogens and commensal bacteria 
can penetrate the dense mucin layer by proteolytic degradation (28,29)	   and a 
subset of commensal bacteria can penetrate the outer mucin layer and break 
down and metabolize the O-linked glycans attached to Muc2 (30-32). 
Commensal microbes enhance mucin production by goblet cells in a 
MyD88-dependent fashion, and germ-free or antibiotic-treated mice have 
markedly reduced levels of mucin. The thickness, density and composition of 
mucin differ in the stomach, small intestine and colon (33,34). The ability of 
bacteria to penetrate the mucus layers along the gut differs, with greater 
mucus penetration in small intestine than either stomach or colon (33). MUC1 
expression in the stomach and small intestine has been implicated in 
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resistance to Campylobacter jejuni and Helicobacter pylori infection	   (35,36) 
while MUC2 provides resistance to enteric Salmonella typhimurium infection  
(37). In addition to functioning as a barrier against penetration by luminal 
bacteria, MUC2 also conditions lamina propria dendritic cells to become 
tolerizing, thereby reducing inflammatory responses to absorbed substances  
(38). Goblet cells have recently been shown to deliver antigens to lamina 
propria dendritic cells, providing a potential delivery pathway to facilitate 
mucin-mediated tolerization of antigen presenting cells (39).    
Below the mucin layer, intestinal epithelial cells form a continuous 
barrier that is one cell layer thick. Intestinal epithelial cells absorb a wide range 
of nutrients, including proteins, carbohydrates and fats, but exclude bacteria. 
Achieving the right balance between nutrient absorption and microbial 
exclusion is critical for optimal health, and deviation from this balance is 
deleterious to the host. Intestinal epithelial cells express innate immune 
receptors, but receptor positioning, i.e. apical versus basal, minimizes 
unnecessary activation by harmless commensals in the intestinal lumen while 
enabling rapid defensive responses when the barrier is breached. For 
example, TLR5, the innate immune receptor specific for bacterial flagellin, is 
not expressed on the apical surface of epithelial cells, where flagellin is 
presumably present at high concentrations (40). Deletion of MyD88 in 
intestinal epithelial cells reduces production of mucin and antibacterial 
peptides and increases susceptibility to infection (41). Certain components of 
the inflammasome, such as NLRP6, are selectively expressed by intestinal 
epithelial cells and can influence the composition of the intestinal microbiota 
by inducing IL18 expression (42) (Figure 1.1).  
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Figure 1.1. Maintenance of intestinal homeostasis in the GI tract. The 
intestinal epithelial surface is coated with a layer of mucus that has a pivotal role 
in intestinal barrier function. This mucus layer is organized by MUC2 mucin 
glycoproteins that polymerize into a gel-like structure preventing luminal bacteria 
from coming into contact with epithelial cells. In the large intestine, two mucus 
layers protect the colonic epithelia: a bacteria-free, dense, inner layer followed by 
an outer layer that harbors mucus-degrading bacteria. In contrast, a single 
loosely attached layer of mucus lines the small intestine. Mucins are produced by 
goblet cells and stored in secretory granules until appropriate stimulation, such 
as signaling through the NLRP6 inflammasome, prompts their release. 
Consistent with high mucus production in the colon, the number of goblet cells is 
much greater in the large intestine compared to the small bowel.  The density 
and composition of luminal bacteria also differ between these two compartments. 
The small intestine harbors ~108 bacteria per gram of content, mostly 
Lactobacillus and Erysipelotrichi and to a lesser extent Enterococcus and 
Enterobacteriaceae. In mice, segmented-filamentous bacteria (SFB) adheres to 
the intestinal surface and enhances the development of Th17 cells and IgA 
production by B cells.  Microbe-associated molecular patterns (MAMPS) 
stimulate the production of antimicrobial peptides (AMPs) from epithelial and 
Paneth cells through activation of pattern-recognition receptors. For example, 
induction of RegIIIγ, an antimicrobial protein that targets Gram-positive bacteria 
and maintains host-bacterial segregation, is mediated through lipopolysaccharide 
(LPS) and flagellin stimulation of TLR4+ epithelial cells and TLR5+ 
CD103+CD11b+ DCs, respectively. DCs and macrophages sample luminal 
antigens and stimulate cytokine production and T cell differentiation. Although 
CX3CR1+ macrophages are the major antigen-sampling mononuclear 
phagocytes in the small intestine, CD103+ DCs have been shown to play a role 
as well. Nearly 1011-1012 bacteria reside in the large intestine. The composition is 
diverse, comprised mainly of Lachnospiraceae, Bacteroides and Clostridium 
groups IV and XIV. Tissue repair and tolerance to commensal and food antigens 
are key factors for maintaining homeostasis in the gut. IL-22 and IL-18 promote 
epithelial cell proliferation and repair; however, excessive and aberrant signaling 
can lead to inflammation and colitis. Tolerance is accomplished by the induction 
of regulatory T cells (Tregs) through several mechanisms. In the small intestine, 
CD103+ DCs take up mucus and stimulate Tregs through IL-10 and TGFβ. 
Although the mechanism has not been elucidated, it is possible that DCs take up 
mucus directly by extending dendrites into the lumen or that goblet cells transfer 
mucus to DCs, as it has been shown with antigen. In the colon, specific Treg-
inducing bacteria have been identified. For instance, Clostridia spp. generate 
metabolites that upon receptor binding stimulate the production of TGFβ from 
epithelial cells. PSA from Bacteroides fragilis enhances Treg function (either 
through direct stimulation of TLR2+ Tregs, or through a TLR2+ DC intermediate) 
while inhibiting pro-inflammatory Th17 responses. !!
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1.2.2. Lamina propria macrophages and dendritic cells 
Immediately below the intestinal epithelial cell layer, complex cell populations 
make up the lamina propria. The lamina propria is a well-vascularized and 
lymph-drained tissue whose functions include facilitating systemic nutrient 
distribution, establishing immune tolerance towards innocuous antigens and 
microbes and providing immune defense against potentially pathogenic 
microbes that emerge from bacterial populations inhabiting the intestinal 
lumen. Mesenchymal stromal cells of the intestinal lamina propria help 
orchestrate immune responses by responding to microbe-derived molecules 
that trigger MyD88-mediated signals and potentially other innate immune 
signaling pathways (43). While the role of stromal cells in the lamina propria is 
likely underappreciated and under-investigated, great progress has been 
made in the last decade in our understanding of the myeloid-derived 
macrophage and dendritic cell populations of the gut (44,45). 
 Given the density and complexity of microbial populations in the 
intestinal lumen and the obvious benefits of mucus and epithelial cell-mediated 
segregation of these organisms from underlying tissues, the initial revelation 
that myeloid cells disrupt inter-epithelial cell tight junctions and extend 
processes into the intestinal lumen was both astounding and disquieting  
(46,47). Subsequent studies implicated CX3CR1-expressing myeloid derived 
cells as the key population accessing the intestinal lumen and taking up 
pathogenic organisms such as Salmonella typhimurium	  (47). CD103+ dendritic 
cells of the lamina propria, which have been implicated in the transport of 
bacteria and antigens to draining mesenteric lymph nodes and in the induction 
of tolerance by producing retinoic acid (48) have also been found to patrol 
between intestinal epithelial cells and extend dendrites into the intestinal 
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lumen, taking up pathogenic bacteria such as Salmonella typhimurium and 
non-pathogenic commensal bacteria and transporting them to draining lymph 
nodes (49) (Figure 1.1).  The contribution of the commensal flora to microbial 
transport by lamina propria residing myeloid derived cells was recently 
investigated, with the finding that antibiotic treatment or MyD88-deficiency 
increased the delivery of bacteria to mesenteric lymph nodes and enhanced 
specific T cell and antibody responses (50).   
The identity of the cell populations capable of delivering bacteria to 
draining lymph nodes remains somewhat controversial, with some studies 
suggesting that CX3CR1+ mononuclear phagocytes transport bacteria (50) 
while most other studies implicate CD103+ dendritic cells (51). It is likely that 
this controversy in part stems from varied dendritic cell (DC) definitions and 
the plasticity of inflammatory monocytes infiltrating the intestinal lamina 
propria, particularly during intestinal inflammation. For example, CCR2+Ly6Chi 
monocytes give rise to CX3CR1+ mononuclear phagocytes, and, once 
differentiated, they appear to become non-migratory. However, under 
inflammatory conditions, CCR2+Ly6Chi monocytes can differentiate into 
migratory DCs and prime T lymphocytes (52,53). 
  
1.2.3. Innate immune signaling in the intestinal wall 
Activation of the innate immune system by microbial stimulation of innate 
immune receptors is an essential early step in defense against infection by 
pathogenic organisms. However, innocuous and potentially beneficial 
colonizing bacteria are composed of molecules that can bind innate immune 
receptors and potentially trigger inflammatory responses. Triggering of some 
innate immune receptors, however, can also induce tolerance by reducing 
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inflammatory responses. Indeed, development of the mucosal immune system 
is in part dependent on innate immune receptor triggering by commensal 
microbes in the intestinal lumen (54). Colonization of the murine gut with the 
anaerobic bacterium Bacteroides fragilis and its production of polysaccharide 
A (PSA) enhances T cell development and differentiation (55). PSA is believed 
to promote T regulatory cell development and inhibit Th17 responses by 
stimulating TLR2 (56) (Figure 1.1). In this setting, TLR2 signaling occurs in 
part via Gadd45a in intestinal dendritic cells upon exposure to B. fragilis outer 
membrane vesicles containing PSA (57). Although the specific DC population 
that responds to PSA stimulation in the colon has not been identified yet, a 
recent study suggests that plasmacytoid dendritic cells might have a role since 
transfer of TLR2-/- bone marrow-derived pDCs rendered mice susceptible to 
colitis (58).	  
Intestinal epithelial cells express antimicrobial molecules, including the 
bactericidal C-type lectin RegIIIγ, in response to gut colonization by 
commensal bacteria (59). Microbe-derived molecules drive RegIIIγ expression 
by stimulating TLRs (60,61). RegIIIγ expression reduces bacterial colonization 
of the dense mucus layer associated with intestinal epithelial cells, thereby 
reducing microbial contact with the epithelium (62,63). RegIIIγ binds to 
peptidoglycan by its lectin domain, and more recent studies of closely related 
RegIIIα demonstrated that bactericidal activity results from association with 
bacterial phospholipids and the formation of a hexameric structure that 
produces a pore in the bacterial membrane (64). In contrast to RegIIIα, which 
is inhibited by Gram-negative lipopolysaccharide (LPS), RegIIIβ has 
bactericidal activity against Gram-negative bacteria by lectin-mediated 
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association with LPS and, at least in part, pore formation in the Gram-negative 
outer membrane  (65,66).    
Which TLRs contribute to immune defense versus tolerance induction in 
the gut remains incompletely resolved. TLR5 has been investigated most 
extensively. While early studies suggested that TLR5 is expressed on the 
basal surface of intestinal epithelial cells, subsequent studies demonstrated 
that TLR5 is predominantly expressed on lamina propria DCs, and that TLR5-
expression on lamina propria DCs facilitates the development the Th17 T cells 
and IgA-producing cells (67,68). Systemic administration of bacterial flagellin, 
the microbial ligand for TLR5, induces the expression of RegIIIγ by intestinal 
epithelial cells along the entire length of the small intestine, and provides 
significant protection against intestinal colonization by Vancomycin-resistant 
Enterococcus (VRE) (69) and infection by Clostridium difficile (70). Systemic 
flagellin rapidly induces expression of IL23 by CD103+CD11b+ lamina propria 
DCs, as noted above, which in turn stimulates IL22 production by ILC3 cells, 
which then leads to RegIIIγ expression by intestinal epithelial cells (71) 
(Figure 1.1).  
Although TLR5 stimulation can promote innate immune defenses 
against intestinal infection, TLR5 signaling, under homeostatic conditions, 
reduces gut inflammation and metabolic syndrome (72). In some mouse 
colonies, TLR5-deficiency is associated with development of spontaneous 
colitis and massive weight gain with parallel development of metabolic 
syndrome. This association has been attributed to alteration of the intestinal 
microbiota, including expansion of proteobacterial populations, resulting from 
deficient TLR5 signaling (73). In the absence of TLR5, flagellin specific IgA 
levels are reduced which appears to increase the expression of flagellin and 
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invasion of flagellated bacteria into sub-epithelial tissues (74). While some 
studies have demonstrated that TLR5-deficiency results in the development of 
obesity and metabolic syndrome (72), this finding is not seen in all TLR5-
deficient mouse colonies  (75).    
Flagellin and TLR5, while contributing to intestinal defense against 
microbial pathogens, only represents a part of the entire story. Oral 
administration of DNA isolated from the gut flora, for example, corrects innate 
immune antimicrobial responses in antibiotic treated mice (76) and oral 
administration of LPS corrects antibiotic-induced innate immune deficiency in 
the gut and enhances resistance against VRE (77). The extent to which TLR-
mediated signals influence the composition of the intestinal microbiota is 
controversial. Comparison of wild type C57BL/6 mice with littermate control 
TLR2, TLR4, TLR5, TLR9 and MyD88 deficient mice did not detect differences 
in their luminal or mucosa-associated ileal, cecal or fecal microbiota under 
homeostatic conditions and following recovery from antibiotic treatment (78).  
This study demonstrated that microbiota composition was largely determined 
by familial transmission of the microbiota and that the composition of bacterial 
populations inhabiting the gut can drift over time as distinct breeding colonies 
are kept in isolation from each other.  
Defects in innate immune signaling have also been implicated in 
microbiota-mediated development of inflammatory bowel disease, obesity and 
obesity-associated steato-hepatitis (79). Deficiency of the NLRP6 
inflammasome subunit in mice is associated with a shift in colonic microbiota 
composition that leads to inflammatory bowel disease and steato-hepatitis  
(42,80). Transfer of the aberrant microbiota from NLRP6-knockout mice to wild 
type mice resulted in the development of these inflammatory diseases, 
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suggesting that loss of NLRP6 alters the microbiota into one that is pro-
inflammatory or, in other words, that NLRP6 signaling in intestinal epithelial 
cells controls the composition of the microbiota and steers it into an anti-
inflammatory state. In part, this process is mediated by IL18-mediated 
signaling (42). Another important mechanism by which NLRP6 modulates 
microbiota composition is by regulating intestinal goblet cell secretion of mucin 
(Figure 1.1). NLRP6 facilitates goblet cell autophagy and also exocytosis of 
mucin granules, and in its absence mucin production is markedly reduced  
(81). Reduced mucin production renders mice more susceptible to infection by 
intestinal pathogens, as noted above.   
While inflammasome signaling in intestinal epithelial cells contributes to 
antimicrobial defense, inflammasome signaling following systemic infection 
can have adverse effects.  For example, mortality following systemic spread of 
a pathogenic strain of Escherichia coli was mediated in part by the Naip5/Nlrc4 
inflammasome (82). In contrast, systemic absorption of microbial molecules 
from the gut, such as peptidoglycan fragments, can trigger Nod2 signaling and 
activate circulating neutrophils, thereby enhancing resistance against infection 
by Streptococcus pneumoniae and Staphylococcus aureus (83). Nod2 
signaling in the gut also acts locally, by promoting inflammatory monocyte 
recruitment into the gut during Citrobacter rodentium infection (84). Studies 
with germ-free mice demonstrated a systemic effect of microbial colonization 
on mononuclear phagocytes. Specifically, mononuclear phagocytes from 
germ-free mice were hypo-responsive to microbial stimulation, a result of 
aberrant chromatin modification of innate immune response genes (85). These 
studies are revealing the complexity of innate immune recognition and 
responses in mucosal tissues, and it is likely that many more examples of pro-
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inflammatory antimicrobial responses and contrasting anti-inflammatory or 
tolerizing responses will be discovered in the coming years.  
 
1.2.4. Innate lymphocytes and the intestinal microbiota 
Innate lymphocytes derive from common lymphoid progenitors, depend on 
common γ-chain signaling, the ID2 transcriptional regulator and differentiate 
under the control of specific transcriptions factors that are shared with T 
lymphocytes into an array of phenotypes that are categorized as ILC1 (T-bet 
dependent and IFN-γ producing), ILC2 (GATA-3 dependent and IL4, IL13 
producing) and ILC3 (RORγt dependent and IL17 and IL22 producing).  ILCs 
represent an important arm of the innate immune defense system, at the level 
of orchestrating immune tissue development and, more directly, antimicrobial 
defenses (86). 
 A subset of ILC3 cells contributes to innate immune tissue development 
in the gut by producing lymphotoxin a and lymphotoxin b.  The ILC3 cells 
involved in this process are referred to as Lymphoid Tissue inducer (LTi) cells 
and their existence depends on the RORγt transcription factor. Soluble 
lymphotoxin a facilitates the production of T cell dependent IgA in the gut, 
while lymphotoxin b on the surface of ILC3s promotes T cell independent IgA 
production (87). In utero development of LTi cells depends on maternal 
retinoid intake, and retinoic acid in the developing fetus is required for RORγt 
induction and LTi development (88). 
 ILCs play essential roles in defense against intestinal bacteria and also 
non-pathogenic bacteria that cross the intestinal epithelial barrier and reside in 
gut-associated lymphoid tissues. Upon deletion of IL22-producing ILC3s, 
lymphoid tissue-residing bacteria such as Alcaligenes can disseminate and 
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drive systemic flares of inflammation (89). Because ILCs and differentiated T 
lymphocytes can express overlapping phenotypes, and because depletion of 
ILCs often also results in depletion of T lymphocytes, it has been challenging 
to distinguish the roles of these cell populations in the induction of 
inflammation and during defense against infection. Using ILC-specific 
depletion strategies, it was found that the absence of ILC3s dysregulated T 
cell responses to the commensal flora. Furthermore, this process required 
MHC class II expression by ILC3s (90). While this finding suggests that 
responding T lymphocytes may interact directly with MHC class II-expressing 
ILC3s, the role of ILC3-mediated antigen-presentation remains unclear. IL22 
expression by ILC3s is promoted by the aryl hydrocarbon receptor (Ahr), and 
mice lacking Ahr have markedly reduced numbers of IL22-producing ILC3s.  
Surprisingly, Ahr-deficiency results in increased numbers of Th17 cells, 
potentially the result of increased intestinal colonization by Segmented 
Filamentous Bacterium (SFB) (91) and also increases the risk of spontaneous 
colitis. ILC3s were recently also shown to be a major source of GM-CSF 
following stimulation by IL1β, which is produced by mononuclear phagocytes 
upon stimulation by microbial molecules. In turn, GM-CSF acts upon 
mononuclear phagocytes to enhance their effector functions (92). The 
interactions between myeloid cells, ILCs, T lymphocytes, B lymphocytes are 
complex and our knowledge of these relationships is far from complete.  
Indeed, novel cell populations, such as CD71+ erythroid cells, which were 
recently demonstrated to attenuate inflammatory responses against newly 
colonizing intestinal bacteria in the neonate by producing arginase-2, are 
being discovered and assigned functional roles in the relationship between the 
host immune system and colonizing microbes (93).      
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1.3. ADAPTIVE IMMUNE DEFENSES AND THE INTESTINAL 
MICROBIOTA 
Antibody and T lymphocyte mediated recognition of intestinal bacteria 
contributes to immune defense and to the pathogenesis of intestinal and 
systemic inflammatory diseases (94). In parallel with advances in our 
understanding of the complex microbial populations inhabiting the gut and the 
more detailed characterization of individual members of the microbiota, recent 
studies have begun to define the specificity of antibody and T cell responses 
to intestinal microbes and the mechanisms driving microbe-mediated 
differentiation of immune cells. 
 
1.3.1. Secretory IgA 
While the intestinal microbiota influences systemic antibody responses, as 
demonstrated by increased serum IgE levels in germ-free mice (95), induction 
of secreted IgA in response to intestinal bacteria is particularly important for 
antimicrobial defense and intestinal microbiota homeostasis. Secretory IgA 
provides defense against intestinal pathogens and its absence has been 
implicated in the expansion of some commensal bacterial populations such as 
SFB (96) and in the maturation of the intestinal microbiota during neonatal life  
(97). Colonization of the murine small intestine with SFB and its ability to 
induce IgA was established by studies over 15 years ago (98), and recent 
studies demonstrate that SFB induces Peyer’s patch development and IgA 
secretion (99) (Figure 1.1).   	  
The PD-1 inhibitory receptor regulates the development of T follicular 
helper cells in Peyer’s patches and, in its absence, promotes precursor cells 
that produce IgA with lower affinity for intestinal bacteria, ultimately affecting 
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microbiota composition (100). Kinetic analyses of intestinal IgA responses 
against commensal bacteria suggest that specific antibodies can be secreted 
for prolonged periods but that they are also dynamic and that new IgA 
antibodies are generated following shifts in microbiota composition (101).  
Deep sequencing of the IgA antibody encoding genes of mice revealed a very 
broad repertoire, with many distinct specificities and with increasing diversity 
with aging (102). While secreted IgA, by virtue of its specificity, influences 
microbiota composition, some IgA-producing plasma cells also produce TNF 
and iNOS and depletion of these cells alter microbiota composition and 
decrease resistance against infection (103). Thus, IgA producing plasma cells 
may augment defensive strategies that have largely been attributed to 
myeloid-derived cell populations. 
 
1.3.2. Th17 cells 
SFB also contributes to the differentiation of Th17 cells in the murine small 
intestinal lamina propria (25,104). SFB appears to have a unique ability to 
penetrate the small intestinal mucus layer and directly contact the surface of 
intestinal epithelial cells, a characteristic that likely contributes to its ability to 
drive the differentiation of Th17 T cells (Figure 1.1). Whole genome 
sequencing of SFB revealed a reduced genome size compared to other 
Clostridiales and its dependence on exogenous amino acids, suggesting that 
this organism is highly adapted to and dependent upon its mammalian host  
(105). Two recent studies have investigated the antigen specificity of Th17 
cells induced by SFB mono-colonization and discovered that the majority of T 
cells belonging to this subset are specific for SFB. Thus, without apparent 
invasion of the lamina propria, SFB induces a broad Th17 response directed 
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against several SFB encoded antigens (106) that depends on MHC class II 
presentation by lamina propria dendritic cells and is independent of secondary 
lymphoid tissues (107). While T cell responses to commensal bacteria can be 
induced by intestinal infections that destroy the epithelial cell layer and induce 
potent inflammatory responses (108), the response to SFB is distinct and 
occurs in the presence of an intact epithelial barrier and in the absence of 
apparent inflammatory cell infiltration of the lamina propria.   
Although not specific to SFB, induction of IL1β in intestinal 
macrophages (a.k.a. mononuclear phagocytes) by gut microbiota has been 
implicated in the induction of Th17 T cells by binding to T cell expressed IL1 
receptor	  (109). Recent studies have demonstrated that light-cycle disruption in 
mouse colonies can promote the differentiation of Th17 cells (110). This study 
demonstrated that the REV-ERBa transcription factor, which is implicated in 
regulation of the circadian clock, enhances NFIL3 activity, which in turn 
interferes with RORγt binding to its promoter. Thus, interference with REV-
ERBa expression reduces NFIL3 activity and enhances Th17 development. 
This finding suggests that sleep abnormalities or frequent challenges to the 
baseline circadian rhythm of mammals may incrementally increase Th17 
development and, potentially increase the risk of inflammatory diseases. 
 
1.3.3. Regulatory T cells 
The intestinal lumen contains a wide range of microbial inhabitants and 
ingested antigens that are potential inducers and targets of T cell responses.  
Regulatory T cells limit naïve T cell differentiation into effector cells that can 
target many of the innocuous antigens that are present in the intestinal lumen.  
In their absence, inflammatory diseases involving the gut occur rapidly and 
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can have lethal consequences. Recent studies have identified bacterial 
species that drive intestinal Treg development. Colonization of mice with 
altered Schaedler flora, which consists of 8 distinct bacterial species, induced 
colonic Treg cells in germ free mice (111) and prevented the development of 
colitis. Characterization of colonic Treg cells induced by commensal bacteria 
revealed that their TCR repertoire was distinct from Tregs in other sites, 
suggesting that colonic Tregs are derived from circulating naïve CD4 T cells  
(112). Remarkably, induction of colonic Treg cells can be driven by 
colonization with a single bacterial strain of Bacteroides fragilis that expresses 
polysaccharide A (113). The ability of bacteria belonging to the Bacteroidetes 
phylum to drive Treg cell differentiation was also demonstrated by colonizing 
germ-free mice with different mixtures of human fecal bacterial cultures that 
included Bacteroides caccae, B. thetaiotaomicron, B. vulgatus, B. massiliensis 
and Parabacteroides distasonis (114). Other studies have demonstrated that 
murine and human derived fecal microbes that belong to Clostridium clusters 
IV and XIVa drive Treg cell development in the murine colon (22,23) in part by 
inducing TGFβ production by intestinal epithelial cells (Figure 1.1). Optimal 
Treg development in mice can be induced by colonization with 17 human-
derived strains belonging to these Clostridia groups (23,115). Trafficking of 
Treg cells to colonic lamina propria is mediated by the GPR15 heterotrimeric 
guanine nucleotide-binding protein coupled receptor, the expression of which 
is modulated by the gut microbiota  (116). One mechanism by which Tregs are 
induced involves the intestinal microbiota up-regulation of Uhrf1 expression, 
which DNA methylates the cyclin-dependent kinase inhibitor p21 promoter, 
thereby inhibiting its transcription and promoting Treg proliferation (117). 	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1.4. DIET, VITAMINS, METABOLISM, IMMUNITY AND THE INTESTINAL 
METABOLOME 
Food digestion, nutrient and vitamin absorption, immune defense and bacterial 
and host metabolism are interrelated and interdependent processes occurring 
in the gut. The implications of these interactions for the mammalian host are 
profound. The mechanisms by which commensal bacteria contribute to host 
metabolism are increasingly being defined (118). Given the complexity of 
intestinal microbial populations, one approach to determine the impact of 
specific bacterial species on host metabolism has been to colonize germ free 
mice with individual bacterial strains and measure the impact on host gene 
expression (119). This study demonstrated that two bacterial species, 
Bifidobacterium longum and Bacteroides thetaiotaomicron have distinct effects 
on gene expression by intestinal epithelial cells, but also influence each 
other’s gene expression patterns. Ingestion of different dietary carbohydrates, 
such as fructose-based polysaccharides, can drive the selective expansion of 
bacterial species that encode the appropriate hydrolytic enzymes and can 
thereby alter microbiota composition (120). The impact of altered microbiota 
composition can be profound, in some cases leading to obesity that can be 
reversed by transfer and expansion of specific members of the Bacteroidetes 
phylum (121). Changes in diet can rapidly alter the composition of the human 
fecal microbiota (122), with animal-based diets reducing the density of bacteria 
belonging to the Firmicutes phylum and increasing organisms associated with 
bile tolerance. Pregnancy has also been associated with changes in the 
intestinal microbiota towards a composition that, upon transfer into germ-free 
mice, increases adiposity and reduces insulin sensitivity (123).  
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 Vitamin A is an essential dietary component and is metabolized into 
retinoic acid, which plays an important role in T cell differentiation, including 
development of Treg cells (124-126). Ingested vitamins, such as vitamin B12, 
are also of benefit to the microbiota and recent studies revealed that the 
intestinal symbiont B. thetaiotaomicron expresses three non-redundant vitamin 
B12 receptors that can each confer competitive advantages to the bacterial 
strain, depending on the presence of distinct vitamin B12 analogs (127).  
Intestinal bacteria can also produce vitamins, such as vitamin B3 (a.k.a. 
niacin) and signal via G-protein-coupled receptor (GPR) 109A and reduce 
intestinal inflammation (128). Recent studies have demonstrated that a dietary 
switch from carbohydrates to tryptophan leads to production of tryptophan 
metabolites by intestinal microbes that enhance signaling via the aryl 
hydrocarbon receptor, in turn leading to greater IL22 production (129). The 
impact of microbiota-mediated metabolism of ingested nutrients on host health 
can also be negative, as demonstrated by studies of L-carnitine, a 
trimethylamine that is acquired by meat ingestion. Conversion of L-carnitine to 
trimethylamine-N-oxide by microbiota members that are expanded in meat-
eating individuals led to increased progression of atherosclerosis in mice 
(130). 
 It is clear that intestinal microbes can dramatically alter the absorption 
and metabolism of orally administered medications. Recent studies have 
demonstrated, for example, that some strains of Eggerthela lenta, a member 
of the human microbiota, can inactivate the cardiac drug digoxin, and that 
changes in diet can alter in vivo metabolism of the drug, leading to different 
drug levels (131). For a drug like digoxin, which has a relatively narrow 
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therapeutic window of activity and potentially lethal toxicities, changes in its 
metabolism by intestinal microbes can have serious clinical implications. 
While most studies of the microbiota have focused on microbiota 
composition, determined either by deep bacterial 16S rRNA gene sequencing 
or shotgun sequencing of fragmented bacterial DNA, recent studies have 
started to investigate the bacterial transcriptome and metabolome.  Analysis of 
the bacterial transcriptome in the gut demonstrated that many genes and their 
respective transcripts are similarly abundant, while genes associated with 
sporulation and amino acid synthesis are often down-regulated and genes 
involved in ribosome biogenesis and methanogenesis are up-regulated (132). 
Administration of xenobiotics to mice can dramatically alter gene expression 
by intestinal microbes, with transcript fluctuations greatly exceeding the 
quantitative changes in the representation of different bacterial taxa (133).  
Beyond determination of the microbiota transcriptome, mass 
spectrometric analysis of microbially produced or modified metabolic products 
promises to provide new insights into the role of intestinal microbes in health 
and disease (134). The impact of the microbiota on a wide range of 
metabolites was revealed by treatment of mice with antibiotics and 
demonstrated that over 87% of metabolites, including bile salts, eicosanoids 
and steroid hormones, were affected by antibiotic-induced shifts in the 
microbiota (135). The metabolomic changes induced by antibiotic 
administration have been implicated in the development of adiposity and have 
been suggested to contribute to the ongoing obesity epidemic (136).  
Administration of fecal microbiota from different humans to germ-free mice 
demonstrated conserved metabolite differences that could be detected by 
mass spectrometry-based metabolomic assays of urine samples (137).  
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1.4.1. Short-chain fatty acids and bile salts 
Among the metabolites that are being characterized in the intestinal lumen, 
short-chain fatty acids (SCFAs) and bile salts stand out as having clearly 
demonstrable roles in immune development and defense against infection. 
SCFAa include acetate, butyrate and propionate and are produced by 
fermentation of fiber and other polysaccharides by a range of intestinal 
bacteria (138). Bacteria belonging to the Bifidobacterium genus can produce 
acetate, which reduces the susceptibility of the colonic epithelium to damage 
caused by the Escherichia coli O157:H7 Shiga toxin (20). In this setting, a 
Bifidobacterium-expressed transporter pumps acetate into the intestinal lumen  
(139). SCFAs produced by intestinal microbes stimulate the GPR43 expressed 
by host inflammatory cells and reduce inflammation, and mice with a deletion 
of GPR43 have enhanced colitis and arthritis upon induction of inflammation 
(140). SCFAs, and butyrate in particular, have recently been demonstrated to 
regulate extrathymic Treg cell development in a GPR43 dependent manner 
(141-143). Butyrate and propionate administration enhances histone 
acetylation in the promoter of the Foxp3 locus, potentially by inhibiting histone 
deacetylase function.  
Bile salts released into the intestinal lumen can impact the composition 
of the microbiota, and commensal microbes can alter the composition of 
intestinal bile salts.  Ingestion of milk fats, for example, increases production of 
taurocholate by the liver, which, in turn, leads to a bloom of the bacterial 
species Bilophila wadsworthia (144). B. wadsworthia can enhance the 
development of colitis in IL10 deficient mice, demonstrating the indirect 
mechanism by which dietary changes can alter the risk of inflammatory 
diseases. Antibiotic treatment, on the other hand, can alter the gut microbiota 
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and eliminate microbes that deconjugate primary bile salts and also 
dehydroxylate primary bile salts to produce secondary bile salts. The 
conversion of primary to secondary bile salts has been shown to be an 
important mechanism of colonization resistance against C. difficile (145) and 
may potentially be implicated in clearance of other intestinal pathogens.   
 
1.5. MICROBIOTA-MEDIATED RESISTANCE TO INFECTION 
 The ability of the normal microbiota to confer resistance to infection became 
apparent in the decades following the introduction of broad-spectrum 
antibiotics with the discovery that antibiotic-treatment could render mice much 
more susceptible to a range of intestinal infections (146-149). In the last 
decade, significant progress has been made in our understanding of the 
mechanism by which the microbiota provides colonization resistance (150-
152). These studies are revealing that colonization resistance can be 
mediated by direct interactions between different bacterial species or by 
indirect mechanisms that either involve stimulation of the host’s innate immune 
system, which induces expression of antimicrobial factors, or modification of 
host metabolic products into molecules that inhibit pathogenic organisms. 
 Antibiotics can induce dramatic and long-lasting changes to the 
microbiota, with expansion of some species and loss of others (14,153,154).  
Antibiotic treatment enhances susceptibility to infection by S. typhimurium and 
C. rodentium, and resistance to these infections has been associated with the 
presence of obligate anaerobes belonging to the Bacteroidetes phylum (155-
157). The emergence of highly antibiotic-resistant bacterial pathogens 
represents a growing clinical problem. Many of the most antibiotic-resistant 
pathogens densely colonize the intestinal tract of patients following treatment 
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with antibiotics (14,158). Vancomycin-resistant Enterococcus (VRE) is one 
such intestinal colonizer and can achieve very high densities in the small 
intestine and colon following antibiotic-mediated depletion of the microbiota. 
Although innate immune activation via TLR4 or TLR5 stimulation can 
enhance resistance to VRE colonization by stimulating the production of 
RegIIIγ expression in the small intestine (69,77), it is not sufficient to provide 
complete protection against colonization. Administration of a diverse and 
antibiotic-naïve microbiota to VRE dominated mice eliminates VRE from the 
gut, demonstrating that colonization resistance can be re-established and 
bacteria can be cleared with normal flora administration. Obligate anaerobes 
are essential for clearance, as demonstrated by fractionation of the microbiota 
by anaerobic or aerobic culture and treatment with chloroform to eliminate 
non-spore forming organisms. In addition, transplantation of a microbiota 
containing bacteria from the Barnesiella genus correlated strongly with 
resistance to VRE colonization and with VRE clearance from the gut (159). 
Fecal transplantation is one method to re-establish a complex 
microbiota and has been used in patients with recurrent C. difficile infection  
(160).	   This procedure, which involves obtaining fecal samples from healthy 
donors and administering them to individuals with recurrent C. difficile 
infection, is remarkably effective and, in the recipient, re-establishes a normal 
microbiota that confers resistance to infection. An important and obvious 
concern with fecal transplantation is the potential risk of transmitting unknown 
or uncharacterized infections that the donor may be resistant against but the 
recipient may be susceptible to (161). This concern is difficult to eliminate 
since the complete composition of a fecal sample is difficult to determine. To 
avoid this, defined mixtures of specific bacterial populations must be 
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developed for administration to individuals with specific intestinal infections. In 
the case of C. difficile, Clostridium scindens, a bacterium belonging to the 
Clostridia cluster XIVa, was recently found to increase resistance to infection 
when adoptively transferred into antibiotic-treated mice (145). 
 
1.6. SUMMARY AND CHAPTER OUTLINE 
Some of the many functions the intestinal microbiota exerts on the host include 
the acquisition of nutrients from diet, the development of the immune system 
and colonization resistance. Antibioitc treatment destroys the intestinal 
microbial ecology and increases the risk for pathogen colonization. The focus 
of this dissertation is to 1) determine the impact the opportunistic pathogens 
vancomycin-resistant Enterococcus (VRE) and carbapenem-resistant 
Klebsiella pneumoniae have on each other and on the host and 2) identify 
intestinal bacteria responsible for colonization resistance against VRE. In 
Chapter 2 we examine whether colonization resistance exists between VRE 
and K. pneumoniae, whether they affect the host and where they localize 
within the intestine. In Chapter 3 we characterize a healthy murine microbiota 
that is ampicillin-resistant and can prevent the deleterious effects of ampicillin 
upon transplant. In Chapter 4 we used this ampicillin-resistant microbiota as a 
tool to identify bacterial groups that are associated with resistance to VRE and 
demonstrated that colonization resistance can be restored with only two 
bacterial species, a discovery that has important implications for the 
development of novel probiotic treatments against VRE. 
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Notes 
Adapted from Microbiota-mediated inflammation and antimicrobial defense in 
the intestine. Caballero S and Pamer EG. Annu Rev Immunol. 2015. 
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CHAPTER 2 
 
DISTINCT BUT SPATIALLY OVERLAPPING INTESTINAL NICHES FOR 
VANCOMYCIN-RESISTANT ENTEROCOCCUS FAECIUM AND 
CARBAPENEM-RESISTANT KLEBSIELLA PNEUMONIAE * 
 
2.1. INTRODUCTION 
Antibiotic-resistant bacteria such as vancomycin-resistant Enterococcus 
faecium (VRE) and multi-drug resistant Klebsiella pneumoniae represent a 
growing concern in hospitals worldwide. In the United States, Enterococcus 
spp. and K. pneumoniae account for nearly 10% of all hospital-acquired 
infections and are common causes of bacteremia (162). Vancomycin 
resistance among enterococci has markedly increased since it was first 
described in the mid-1980s (163). Even more alarming, however, is the 
increasing prevalence of carbapenem-resistant Enterobacteriaceae, primarily 
K. pneumoniae, rendering treatment of these infections very challenging  
(164). Broad-spectrum antibiotic exposure, immune suppression and 
intravascular devices increase the risk for colonization and infection with one 
or more antibiotic-resistant bacteria (165). In hospitalized patients, the 
intestine can become densely colonized with drug-resistant organisms. While 
colonization by itself does not directly cause disease, in the event of injury to 
the mucosal barrier colonizing bacteria may translocate beyond the intestinal 
tract, leading to deep tissue and bloodstream infections (166).  
 
* S. Caballero, R. Carter, X. Ke, B. Sušac, I. M. Leiner, G. J. Kim, L.    Miller, L. 
Ling, K. Manova and E. G. Pamer. PLoS Pathog. 2015.  
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Consistent with this, studies have shown that intestinal colonization precedes 
bloodstream infection with VRE or K. pneumoniae, suggesting that loss of 
colonization resistance represents an early step in the progression of these 
infections  (14,158,167).  
Colonization resistance refers to the ability of the microbiota to prevent 
expansion and persistence of exogenously acquired bacterial species, a 
pivotal defense mechanism that can be impaired by antibiotic treatment  
(152,168). Changes in microbiota composition, mainly the elimination of 
specific groups of anaerobic bacteria, lead to VRE domination of the 
gastrointestinal tract in antibiotic-treated mice (14,159). Similarly, colonization 
of mice with K. pneumoniae is facilitated by antibiotic administration (169,170). 
Antibiotic-mediated depletion of commensals also decreases production of 
mucus and antimicrobial effector molecules, potentially increasing the risk for 
bacterial invasion of the intestinal epithelium (62,69,77,157,171).  
The interactions between different bacterial species in the gut are 
complex.  Studies of mice singly colonized with Bacteroides thetaiotaomicron, 
Bifidobacterium longum or co-colonized with both demonstrated that these 
distinct bacterial species impact each other’s transcriptional profile (119). In 
some circumstances, bacterial species work together in assembly-line fashion 
to dismantle complex carbohydrates, where the product of one species 
becomes the substrate for another (172). In other circumstances, however, 
microbial species within the intestine compete for limited nutrients and space 
in order to persist. For example, similarities in carbon utilization by Escherichia 
coli and Citrobacter rodentium lead to competition between these species. 
Niche specialization also results in competition between the same, but not 
different, strains of Bacteroides spp. (17,173). Metabolic overlap and niche 
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restriction, however, can be shared by distinct bacterial species as is the case 
with Salmonella typhimurium and Clostridium difficile which benefit from the 
transient abundance of the same sugars following antibiotic treatment (19). 
Yet, the extent to which metabolic competition between antibiotic-resistant 
microbes contributes to their prevalence and persistence is unknown.  
We sought to investigate the interactions between VRE, K. pneumoniae 
and the host in a murine model of intestinal colonization. Our goal was to 
determine whether intestinal domination by either VRE or K. pneumoniae 
would provide colonization resistance against the other. We found that VRE 
and K. pneumoniae were able to co-exist despite occupying the same 
intestinal sites, while restoration of a normal microbiota by means of a fecal 
transplant displaced both organisms effectively but at different rates.  Antibiotic 
treatment of mice reduced the thickness of the colonic mucin layer, a defect 
that was corrected by K. pneumoniae but not VRE colonization. However, K. 
pneumoniae was more effective than VRE at invading the mucus layer and 
translocating to mesenteric lymph nodes. Our findings demonstrate that highly 
antibiotic-resistant bacteria such as VRE and K. pneumoniae non-
competitively co-occupy the colon but establish distinct relationships with the 
mucosal epithelium.  
 
 
 
 
 
 
 
	   33	  
2.2. RESULTS 
 
2.2.1. VRE and K. pneumoniae coexist in the gastrointestinal tract  
We previously showed that treatment with ampicillin, a broad-spectrum 
antibiotic, renders C57BL/6 mice from Jackson Laboratories highly susceptible 
to VRE colonization (14). Inoculation of ampicillin-treated mice with K. 
pneumoniae also resulted in dense colonization of the colon, with 
approximately 1010 colony-forming units (CFU) per gram of feces 
(Supplementary Figure 2.1B). To assess the impact of VRE and K. 
pneumoniae on each other’s ability to colonize the gut, we performed a series 
of experiments in which ampicillin-treated mice were pre-colonized with VRE 
or K. pneumoniae by gastric lavage and challenged with the other species 3 
days later, at which point the initial colonizer has become established in the 
intestine and reached maximum density (Supplementary Figure 2.1B). Fecal 
levels of K. pneumoniae and VRE were determined by culture beginning one 
day and continuing through 21 days post infection (p.i.) with the challenge 
species (Figure 2.1A). We found that dense colonization with VRE did not 
significantly impact K. pneumoniae colonization levels at any time point over 
the course of the experiment. However, fewer K. pneumoniae were recovered 
from the feces of co-colonized mice on day 1 p.i., suggesting a lag in 
establishment of K. pneumoniae in the presence of VRE shortly after infection 
(Figure 2.1B). On day 21, mono- and co-colonized animals had comparable 
K. pneumoniae burden in the proximal and distal small intestine (duodenum 
and ileum, respectively) as well as in the large intestine (cecum) (Figure 
2.1D). Under this experimental condition, introduction of K. pneumoniae did 
not reduce VRE density in the intestine. Rather, VRE CFU levels were, for the 
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most part, similar in mono- and co-colonized mice although a trend toward 
increased VRE burden was observed on days 1, 14 and 21 post challenge 
(Figures 2.1C and 2.1E).  
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Figure  2.1. Pre-colonization with VRE does not prevent colonization by K. pneumoniae. 
(A) Experimental design. Mice were treated with ampicillin for 29 days. On day 5 of ampicillin 
treatment, mice were inoculated with 5x104 colony-forming units (CFU) of VRE by oral gavage 
or left uninfected. Three days later, half of the VRE-infected mice and the uninfected group were 
challenged with 5x104 CFU of K. pneumoniae (Kpn). (B, C) CFU of K. pneumoniae (B) and VRE 
(C) were quantified in fecal pellets collected at different time points post K. pneumoniae 
inoculation. (D, E) Mice were sacrificed 21 days post K. pneumoniae challenge. K. pneumoniae 
(D) and VRE (E) burden was quantified in the luminal contents from the duodenum, ileum and 
cecum. L.O.D., limit of detection. Data were pooled from two independent experiments (n=10 
per group). (B-E) Data were analyzed by the Mann-Whitney test.
	   35	  
In the converse experiment, challenge of K. pneumoniae-dominated mice with 
VRE resulted in a transient but significant increase in VRE density 1 day p.i. 
but then equivalent density in all intestinal compartments when compared to 
antibiotic-treated mice lacking K. pneumoniae (Figures 2.2A-B and 2.2D). In 
addition, we observed no difference in K. pneumoniae colonization between 
mice challenged with VRE and mice mono-colonized with K. pneumoniae 
(Figures 2.2C and 2.2E). Overall, our results demonstrate that VRE and K. 
pneumoniae neither compete nor synergize with each other upon dense 
colonization of the murine gut.  
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Figure 2.2. Pre-colonization with K. pneumoniae does not prevent colonization by VRE. 
(A) Experimental design. Mice were treated with ampicillin for 29 days. On day 5 of ampicillin 
treatment, mice were inoculated with 5x104 colony-forming units (CFU) of K. pneumoniae 
(Kpn) by oral gavage o left uninfected. Three days later, half of the K. pneumoniae-infected 
mice and the uninfected group were challenged with 5x104 CFU of VRE. (B, C) CFU of VRE 
(B) and K. pneumoniae (C) were quantified in fecal pellets collected at different time points 
post VRE inoculation. (D, E) Mice were sacrificed 21 days post VRE challenge. VRE (D) and 
K. pneumoniae (E) burden was quantified in the luminal contents from the duodenum, ileum 
and cecum. L.O.D., limit of detection. Data were pooled from two independent experiments 
(n=10 per group).  (B-E) ****P<0.0001, by the the Mann-Whitney test. 
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2.2.2. VRE and K. pneumoniae achieve similar densities in the large 
intestine of co-colonized mice  
Because VRE becomes the dominant member of the intestinal microbiota 
within days after administration to antibiotic-treated mice (14), we examined 
how colonization by K. pneumoniae and subsequent VRE challenge would 
impact their relative proportions at different time points p.i. On day 1 post 
challenge, VRE represented 30% of the total fecal bacteria in mono-colonized 
mice, with the remaining 70% constituting bacteria that remained and 
expanded following antibiotic treatment. In mice previously colonized with K. 
pneumoniae, VRE represented 10% of the microbiota and K. pneumoniae 
dominated. However, VRE rapidly expanded in the colon of co-colonized 
animals and within 4 days of inoculation, VRE and K. pneumoniae achieved 
roughly equal densities and remained stable for up to 21 days (Figure 2.3A). 
This ratio was specific to the large intestine since both bacterial species were 
equally abundant in the cecum and colon but VRE dominated over K. 
pneumoniae in the ileum (Figure 2.3B).  
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2.2.3. Fecal bacteriotherapy eliminates established VRE and K. 
pneumoniae intestinal domination 
Transplantation of feces from donor mice that have not been treated with 
antibiotics can eliminate VRE from the intestine of densely colonized mice 
and, in humans, fecal transplantation from healthy donors cures patients with 
recurrent Clostridium difficile infection (159,174). To determine whether the 
kinetics of VRE and K. pneumoniae clearance from the murine intestine 
following fecal transplantation are similar or distinct, we colonized ampicillin-
treated mice with VRE and K. pneumoniae concurrently, terminated ampicillin 
treatment and treated mice with fecal microbiota transplants (FMT) or PBS on 
three consecutive days (Figure 2.4A). VRE and K. pneumoniae colonization 
levels were similar in the feces before FMT administration and remained 
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Figure 2.3. K. pneumoniae and VRE achieve similar densities in the large intestine of 
co-colonized mice. 
Ampicillin-treated mice were inoculated with K. pneumoniae by oral gavage or left uninfected. 
Three days later, half of the K. pneumoniae-infected mice and the uninfected group were 
challenged with VRE. Microbiota composition of mice colonized with VRE alone (V), K. 
pneumoniae alone (K) or both (VK) was determined by sequencing of the V4-V5 region of the 
16S rRNA genes. (A) Fecal microbiota composition at different time points post VRE 
challenge. (B) Ileal and cecal microbiota composition at day 21 of colonization. (A,B) Each 
stacked bar represents the average of five individually-housed mice per time point.  
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elevated in mice that received PBS instead of FMT (Figure 2.4B). However, 
following FMT treatment, K. pneumoniae density in fecal pellets decreased 
within one day and became undetectable within 7 days in all mice (Figure 
2.4C). VRE, on the other hand, was cleared in 60% of the mice but reduced by 
3 logs in the remaining 40%. Increased colonization resistance against K. 
pneumoniae as opposed to VRE was also observed in mice that had not been 
treated with antibiotics  (Supplementary Figure S2.1A). K. pneumoniae was 
also cleared more effectively than VRE from the duodenum, ileum and cecum 
of FMT-treated animals while the density of these bacterial species remained 
high in PBS-treated mice (Figures 2.4D and 2.4E). These findings suggest 
that the mechanisms of microbiota-mediated colonization resistance against 
VRE and K. pneumoniae are distinct or that K. pneumoniae is more 
susceptible to colonization resistance.  
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Figure 2.4. Fecal bacteriotherapy eliminates established K. pneumoniae and VRE intestinal 
domination.
(A) Experimental design. Mice were treated with ampicillin for 8 days. On day 5 of ampicillin 
treatment, mice were simultaneously infected with 5x104 CFU of VRE and K. pneumoniae (Kpn). 
Three days post infection, ampicillin treatment was stopped. Mice were administered PBS or a fecal 
microbiota transplant (FMT) from an untreated mouse on three consecutive days starting on the 
third day after ampicillin cessation. (B, C) VRE and K. pneumoniae burden was quantified in fecal 
pellets at the indicated time points after the last PBS (B) or FMT (C) dose. (D, E) PBS- and FMT-
treated mice were sacrificed on day 10 following the last treatment dose and numbers of K. 
pneumoniae (D) and VRE (E) CFU were quantified in the duodenum, ileum and cecum. L.O.D., limit 
of detection. n ≥ 5 per group. (B-E) **P<0.005 by the Mann-Whitney test.
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2.2.4. K. pneumoniae and VRE reside within the same intestinal regions 
but occupy distinct metabolic niches 
The findings that K. pneumoniae and VRE do not interfere with each other’s 
ability to colonize the gut lumen and that their elimination from the intestine 
following FMT differs suggest that these bacterial species occupy distinct 
intestinal niches. To localize bacteria within the colons of mice we performed 
fluorescence in situ hybridization (FISH) with a universal probe targeting 
bacterial 16S rRNA genes. In mice that had not been treated with antibiotics, 
we detected a dense and morphologically diverse bacterial microbiota that is 
almost completely depleted by ampicillin-treatment (Figures 2.5A-B and 
Supplementary Figures 2.2A-B). FISH analysis of antibiotic-treated mice 
colonized with K. pneumoniae (Kpn), VRE or both with species-specific 
oligonucleotide probes revealed that K. pneumoniae and VRE were most 
abundant in luminal areas adjacent to the colonic epithelial layer and that both 
organisms localized to the same intestinal sites (Figures 2.5C-D and 2.6A-D).  
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Confocal microscopy-based quantification of VRE and K. pneumoniae 
in mono-colonized mice demonstrated that K. pneumoniae and VRE each only 
achieved 10% of the bacterial density detected in antibiotic-naive mice with a 
diverse microbiota (Figure 2.5E). In co-colonized mice, the densities of VRE 
and K. pneumoniae in the colonic lumen were additive, supporting the idea 
that VRE and K. pneumoniae do not interfere with one another and that their 
metabolic needs may differ  (Figure 2.5E). Furthermore, K. pneumoniae and 
VRE were generally occupying overlapping regions within luminal areas 
Figure 2.5. K. pneumoniae and VRE occupy a fraction of the total available space in the 
colon.
(A-E) Visualization of bacterial localization by FISH. Entire colon cross-sections from untreated mice 
(A) and mice treated with ampicillin for 3 weeks (B) were stained with a universal probe that targets 
the 16S rRNA gene of all bacteria. Cross-sections from ampicillin-treated mice colonized with K. 
pneumoniae (C) or VRE (D) for 21 days were hybridized with probes specific for K. pneumoniae 
(Kpn) and Enterococcus, respectively. Sections were counterstained with Hoechst dye to visualize 
nuclei. Images are representative of 5 mice per group. Scale bar, 500 μm. (E) Number of bacteria 
per unit area of whole colon cross-sections. n = 3 per group. ND = non-detectable. Error bars (mean 
± SEM).  **P<0.005, ***P<0.0005 by the Mann-Whitney test.
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closest to the colonic epithelium, although islands of increased bacterial 
density were also detected more centrally in the colonic lumen (Figures 2.6C-
D). To further assess whether VRE and K. pneumoniae compete for space 
within the regions they occupy in the colon, we measured distances between 
neighboring VRE bacteria, between neighboring K. pneumoniae bacteria and 
between neighboring VRE and K. pneumoniae bacteria.  Supporting the notion 
that VRE and K. pneumoniae occupy different metabolic niches, intraspecies 
distances were significantly greater than interspecies distances between VRE 
and K. pneumoniae, suggesting that localized nutrient depletion may promote 
spatial avoidance among competing bacteria while non-competing bacteria 
ignore each other (Figure 2.6E). 
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Figure 2.6. K. pneumoniae and VRE reside within the same intestinal regions but 
occupy distinct metabolic niches. 
(A-D) Spatial localization of K. pneumoniae and VRE in the colon. Colon sections from 
ampicillin-treated mice colonized for 21 days with K. pneumoniae alone (A), VRE alone (B) 
and K. pneumoniae together with VRE (C, D) were hybridized with probes specific for K. 
pneumoniae and Enterococcus. (D) VRE and K. pneumoniae islands (dashed circles and 
square) in the colonic lumen of co-colonized mice. (A-D) All sections were counterstained with 
Hoechst dye to visualize nuclei. Scale bars, 10 μm. Insets, 63X oil objective plus 4X digital 
zoom. Images are representative of at least 5 mice per group. (E) Minimum distance between 
neighboring bacteria determined by confocal microscopy. ns=non-significant; ****P<0.0001, by 
the Mann-Whitney test. 
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2.2.5. Antibiotic treatment and colonization with K. pneumoniae or VRE 
influences the thickness and integrity of the inner mucus layer 
The murine colonic mucus layer consists almost exclusively of the mucin Muc2  
(175). Upon release from goblet cells, Muc2 forms a gel-like layer that coats 
the intestinal epithelium and that is largely impenetrable to bacteria. Beyond 
the thick, epithelium-associated mucin layer is a loosely attached and less 
dense mucin layer that is readily penetrated by intestinal bacteria and that 
serves as a microbial habitat (175,176). Under normal homeostatic conditions, 
bacterial molecules released by the microbiota and host factors regulate the 
production and secretion of mucus (177) and thinning of the colonic mucus 
layer occurs following antibiotic treatment (157). The infectivity of some 
intestinal pathogens, such as C. rodentium and Salmonella enterica sv 
Typhimurium, is enhanced by disruption of the mucus layers in the colon  
(37,69).  
To explore the impact of K. pneumoniae and VRE colonization on the 
colonic mucus layer, we stained colonic sections for Muc2 and measured the 
thickness of the inner mucus layer. While the dense mucus layer was 
significantly reduced in mice treated with ampicillin (Figures 2.7A-B and 
2.7E), mono-colonization of ampicillin-treated mice with K. pneumoniae but not 
VRE resulted in recovery of normal mucus layer thickness (Figures 2.7C-E).  
This indicates that bacterial species differ in their ability to promote mucin 
production and mucus layer generation in the murine colon.  
 
 
 
 
	   47	  
 
 
 
 
 
 
 
 
Fig 7
UntreatedA EAmpicillin-treated
Kpn mono-colonized VRE mono-colonized
Untreated Amp Kpn VRE
0
10
20
30
40
In
ne
r m
uc
us
 la
ye
r 
th
ick
ne
ss
  (
μm
)
****
*** ***
ns
GC
GC
GC
O
i
GC
B
C D
Muc2          DAPI
Figure 2.7. K. pneumoniae and VRE colonization influences the thickness of the inner mucus 
layer.
(A-D) Colon sections from untreated mice (A), ampicillin-treated mice (B) and ampicillin-treated mice 
mono-colonized with either K. pneumoniae (C) or VRE (D) for 21 days were stained with an anti-Muc2 
antibody to visualize the inner and outer mucus layers along with goblet cells (arrows). Double arrows 
denote the inner mucus layer. i, inner mucus layer; o, outer mucus layer; GC, goblet cell. Scale bars, 10 
μm. Images are representative of 5 mice per group. (E) Quantification of inner mucus layer thickness. 
Error bars (mean ± SEM).  n=3-6 mice per group. ns=non-significant; ***P<0.0005, ****P<0.0001, by the 
unpaired Student t test. 
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2.2.6. K. pneumoniae and VRE differ in their ability to invade the colonic 
mucus barrier and translocate to extra-intestinal sites 
To investigate the interactions between K. pneumoniae and VRE with the 
colonic mucin layer, we mono-colonized ampicillin-treated mice and performed 
FISH in conjunction with Muc2 immunostaining to localize bacteria in relation 
to the inner mucus layer (IML). Very few bacteria were detected within the IML 
in antibiotic-naïve mice harboring a diverse microbiota (Figure 2.8A). On the 
other hand, K. pneumoniae was detected within the IML in mono-colonized 
mice, with the extent of mucin penetration varying in different regions of a 
colonic cross-section (Figure 2.8B). VRE also penetrated the IML at different 
regions but to a lesser extent than K. pneumoniae (Figure 2.8C). Image 
analysis of entire colon cross-sections revealed substantially higher bacterial 
numbers in the IML of K. pneumoniae mono-colonized mice compared to 
antibiotic-naïve or VRE mono-colonized animals (Figure 2.8D). Within the 
colonic lumen, however, K. pneumoniae and VRE were similarly associated 
with detached islands of mucus (Figures 2.8B-C).  
To determine whether increased mucus layer penetration by K. 
pneumoniae is associated with increased invasion of deeper tissues, we 
cultured mesenteric lymph nodes (mLNs).  In mono-colonized mice, we 
detected up to 104 live K. pneumoniae in mLNs three weeks p.i. (Figure 2.8E) 
Notably, infection of mLNs by K. pneumoniae was not affected by co-
colonization with VRE, regardless of the order of microbial administration. In 
contrast, we did not recover any live bacteria from mLNs of VRE mono-
colonized animals, perhaps reflecting their reduced penetration of the IML. 
However, challenge of VRE mono-colonized mice with K. pneumoniae resulted 
in VRE translocation to mLNs in 60% of the mice, suggesting that introduction 
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of K. pneumoniae may enhance the ability of VRE to traverse the mucin layer 
and gain access to the intestinal epithelium (Figure 2.8E). Administration of 
fecal microbiota transplants to colonized mice reduced K. pneumoniae 
infection of mLNs (Figure 2.8F), suggesting that isolation of live bacteria from 
mLNs of K. pneumoniae-colonized mice results from continuous seeding of 
the node rather than bacterial growth and persistence in mLNs. Our findings 
demonstrate that K. pneumoniae, upon achieving high density in the intestine, 
can penetrate the dense mucin layer of the colon.  In contrast, VRE access to 
the epithelial layer appears to be more restricted by the mucin layer.  Although 
the ability to penetrate mucus has been associated with pathogenic bacteria, 
our results suggest that among commensal bacterial species mucus 
penetration may correlate with their ability to disseminate beyond the gut 
lumen.  
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Figure 2.8. Differential mucus layer infiltration and translocation by VRE and K. pneumoniae. 
(A-C) Dual immunostaining of colon sections from untreated mice (A) and ampicillin-treated mice 
mono-colonized with either K. pneumoniae (B) or VRE (C) for 21 days using anti-Muc2 and a pan-
bacterial 16S rRNA gene FISH probe. Sections were counterstained with Hoechst dye to visualize 
nuclei. Arrowheads indicate bacteria within the inner mucus layer. Scale bar, 10 μm. Images are 
representative of 5 mice per group. Boundaries of the inner mucus layer (IML) zone were 
determined by the density of Muc2 staining and the stratified organization characteristic of the inner, 
but not the outer, mucus layer. (D) Number of bacteria within the IML. UT, untreated. (E) Numbers of 
VRE and K. pneumoniae in mesenteric lymph nodes of mono-colonized mice and mice pre-
colonized with either VRE or K. pneumoniae (initial strain) and challenged with the opposite strain at 
day 21 post challenge. Data were pooled from two independent experiments. (F) Numbers of VRE 
and K. pneumoniae in mesenteric lymph nodes of mice co-colonized with VRE and K. pneumoniae 
with or without a fecal transplant (FMT) 10 days after receiving the last of three FMT/PBS doses. 
Data were pooled from two independent experiments. L.O.D., limit of detection. (D-F) ns=non-
significant; *P<0.05, **P<0.005, by the Mann-Whitney test. 
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2.3. DISCUSSION 
VRE and K. pneumoniae are two of the most common highly antibiotic- 
resistant bacterial species that cause infections in hospitalized patients. Both 
organisms are oxygen-tolerant facultative anaerobes and principally reside in 
the lower gastrointestinal tract where, under normal circumstances, they are 
minor contributors to a colonic microbiota composed predominantly of oxygen-
intolerant obligate anaerobes. Microbiota analyses have revealed that some 
patients undergoing allogeneic hematopoietic stem cell transplantation have 
marked expansion of VRE or K. pneumoniae in their colonic microbiota  
(14,158), to the point where in many cases these species constitute the 
overwhelming majority of the intestinal bacterial taxa. Our experiments with 
murine models demonstrate that both organisms can undergo massive 
expansion in the gastrointestinal tract of antibiotic-treated mice, occupy the 
same intestinal regions and coexist without exerting any colonization 
resistance against each other.  
The mechanisms that determine bacterial density in the colon remain 
incompletely defined. During broad-spectrum antibiotic treatment the density of 
bacteria in the colon, as determined by quantitative 16S rRNA gene PCR, is 
reduced over 1,000 fold. Nevertheless, upon termination of antibiotic 
treatment, the compositionally-restricted residual flora re-expands to a density 
that is similar to pre-treatment levels (14,154).  Along similar lines, we find that 
VRE and K. pneumoniae achieve densities of 1010 CFU per gram of colonic 
content in antibiotic-treated mice, at which point their growth stops, potentially 
resulting from nutrient depletion or quorum sensing mechanisms that remain 
undefined (178). Because VRE and K. pneumoniae grow independently in the 
colons of antibiotic-treated co-colonized mice, our findings suggest that distinct 
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mechanisms determine maximal bacterial density of these two bacterial 
species. 
Competition for resources has been demonstrated in several in vivo 
colonization studies involving bacteria of the same or closely related species  
(17,173,179,180). In the intestine, heavily glycosylated mucus is a major 
source of energy for bacteria. Commensals that express mucus-degrading 
enzymes, such as Bacteroides thetaiotaomicron, can cleave sugars from host 
glycans and support the growth of other members of the colonic microbiota  
(18,19). Enterococci and γ-Proteobacteria do not express glycosidases that 
degrade mucosal polysaccharides, and thus their carbohydrate utilization is 
limited to less complex sugars (181,182). Some studies have demonstrated 
that mucus-derived carbohydrates, including sialic acid and fucose, transiently 
accumulate following antibiotic-treatment, presumably as a result of 
hydrolases released during bacterial cell lysis, and promote the growth of 
Salmonella and Clostridium difficile (19,183). However, given the transient 
release of these carbohydrates following initiation of antibiotic treatment, it is 
unlikely that this process is sustaining dense and prolonged colonization by 
either VRE or K. pneumoniae. Although E. faecium and K. pneumoniae can 
metabolize monosaccharides, and the range of potential carbon sources for K. 
pneumoniae is broad (184), the in vivo carbohydrate dependencies of these 
two bacterial species remain largely uncharacterized. The lack of competition 
between VRE and K. pneumoniae could potentially be explained by a 
difference in metabolic requirements (i.e. different sugar utilization) and the 
observation that bacteria can switch to alternative nutrient sources in the 
presence of competing strains (185). Further studies that examine the 
metabolic profiles of VRE and K. pneumoniae during mono- and co-
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colonization will be necessary to identify the mechanisms determining their 
density in the intestinal tract.  
In addition to serving as a nutrient source for intestinal bacteria, mucus 
also provides a barrier that keeps bacteria away from the colonic epithelium. 
The intestinal microbiota induces mucin production and antibiotic 
administration results in thinning of the mucus barrier, thereby increasing 
susceptibility to bacterial invasion (157). Pathogens such as Salmonella and 
C. rodentium can penetrate the mucus layer and in the process induce 
increased mucin production, a host defense mechanism that limits bacterial 
invasion  (37,171). Consistent with these studies, we find that K. pneumoniae 
infiltrated the mucus layer while also restoring its thickness to pre-antibiotic 
treatment levels. VRE colonization of antibiotic-treated mice, on the other 
hand, did not induce mucus layer thickening. In addition, VRE did not invade 
the mucus layer to the same degree as K. pneumoniae. It remains to be 
determined whether enhanced mucus production is a consequence of 
bacterial invasion or rather, molecular differences between Gram-negative and 
Gram-positive bacteria.  
In mice with a normal flora and intact TLR signaling, the dense mucus 
layer is largely devoid of bacteria (62,175). Antibiotic treatment, however, 
reduces the expression of antimicrobial molecules such as RegIIIγ (77), 
potentially enabling bacteria to gain access to and survive within the mucus 
layer. Since expression of RegIIIγ in the small intestine is markedly reduced 
as a result of antibiotic treatment (69,77), it is possible that a paucity of host-
derived antimicrobial proteins in the mucin layer renders it more penetrable.  A 
recent study showed that mice harboring high levels of bacteria belonging to 
the Proteobacteria and TM7 phyla have an inner mucus layer that is normal in 
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thickness but penetrable to bacteria (186). Thus, it is also possible that K. 
pneumoniae may induce mucins with abnormal glycosylation or that are 
structurally disorganized.  
Although intestinal colonization with VRE and K. pneumoniae is 
asymptomatic, it increases the risk of extra-intestinal infection, including 
bacteremia (158,187). Consistent with the observed differences in mucus 
infiltration, we found increased K. pneumoniae translocation to mesenteric 
lymph nodes (mLNs) relative to VRE. Co-colonization with K. pneumoniae 
resulted in increased VRE translocation to mLNs, suggesting that K. 
pneumoniae may have opened barriers for the less invasive VRE. The high 
levels of K. pneumoniae observed in mLNs of intestinally dominated mice and 
the complete reduction of bacteria following FMT-mediated intestinal clearance 
of K. pneumoniae suggests that bacteria are not replicating in the mLNs but 
rather are delivered on a continuous basis. Although it is unclear how live 
bacteria are delivered to draining mLNs, recent studies with other bacterial 
pathogens suggest that cells within the colonic lamina propria, including 
CD103+ and CX3CR1+ dendritic cells, may capture K. pneumoniae from the 
luminal environment and carry them to mLNs (49,50). 
Enterococci and γ-Proteobacteria constitute a minor population within 
the human and murine microbiota and are, for the most part, harmless to the 
host unless intestinal homeostasis is perturbed (176). In our murine model, 
intestinal colonization with VRE and K. pneumoniae did not result in detectable 
inflammation of the intestinal wall. In clinical scenarios, however, dense 
intestinal colonization with antibiotic-resistant bacteria is an important risk 
factor for systemic infection and for patient-to-patient spread. We found that 
introduction of a normal microbiota into VRE and K. pneumoniae co-colonized 
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mice resulted in clearance of both bacterial species, albeit at different rates. 
Current studies are focusing on the identification of commensal bacterial 
species that mediate clearance of antibiotic-resistant bacteria. Overall, the 
findings presented here uncovered previously unrecognized features of VRE 
and K. pneumoniae colonization and provide insight into the nature of 
pathogen coexistence, dissemination and ways to eradicate colonization.  
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2.4. MATERIALS AND METHODS 
 
2.4.1.   Mice, bacterial strains and infection. All experiments were carried 
out using 6-8 week-old C57BL/6 female mice purchased from Jackson 
Laboratories and housed in sterile cages with irradiated food and acidified 
water. For experiments involving antibiotic treatment, 0.5g/L ampicillin (Fisher) 
was administered to animals in the drinking water and changed every 4 days. 
Vancomycin-resistant Enterococcus faecium was purchased from ATCC 
(700221). Carbapenem-resistant Klebsiella pneumoniae was obtained from 
the Clinical Microbiology Laboratory at Memorial Sloan-Kettering Cancer 
Center and isolated from blood cultures of a patient. Both bacterial strains 
were grown at 37oC in Brain Heart Infusion (VRE) or Luria-Bertani (K. 
pneumoniae) broth to early stationary phase and diluted in phosphate buffered 
solution (PBS) to 105 colony-forming units (CFU). For infection experiments, 
5x104 CFU of VRE and/or K. pneumoniae were administered by oral gavage in 
a 200μl volume on the fifth day of ampicillin treatment. For simultaneous 
infection of VRE and K. pneumoniae (Fig 2.4), inocula were mixed in a 1:1 
ratio prior to administration. Mice were single-housed at the time of infection 
and kept on ampicillin until the end of the experiment unless otherwise 
specified. Animals were maintained in a specific pathogen-free facility at 
Memorial Sloan-Kettering Cancer Center. All mouse handling, cage changes 
and tissue collection were performed in a biosafety level 2 facility wearing 
sterile gowns, masks and gloves. 
 
2.4.2.   Quantification of VRE and K. pneumoniae burden. Fecal samples 
and intestinal contents from the duodenum, ileum and cecum were weighed 
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and resuspended in 1 ml of PBS. Tenfold dilutions were plated on Difco 
Enterococcosel (supplemented with 8 μg/ml vancomycin; Novaplus and 100 
μg/ml streptomycin; Fisher) and Luria-Bertani (supplemented with 50 μg/ml 
neomycin; Sigma-Aldrich and 100 μg/ml carbenicillin; LabScientific) agar 
plates for the specific detection of VRE and K. pneumoniae, respectively. 
Mesenteric lymph nodes were mashed through a 40 μm filter, resuspended in 
PBS and plated directly onto selective plates.   
 
2.4.3.  Fecal microbiota transplantation (FMT). A fecal pellet from an 
untreated C57BL/6 mouse was resuspended in 1ml of PBS under anaerobic 
conditions and 200μl was administered per mouse via oral gavage starting on 
the third day of ampicillin cessation. This process was repeated on the fourth 
and fifth days for a total of three consecutive FMT doses.  
 
2.4.4.  DNA extraction, V4-V5 16S rRNA gene amplification, multiparallel 
sequencing and sequence analysis. Fecal samples and intestinal contents 
were frozen immediately after collection in a dry ice/ethanol slurry and stored 
at -80oC. DNA was extracted using the phenol-chloroform and bead beating 
method described previously (14). The V4-V5 region of the 16S rRNA gene 
was amplified and sequenced with the Illumina Miseq platform as described 
previously (145). Sequences were analyzed using version 1.33.3 of the 
MOTHUR pipeline (7) as described in Buffie et al., 2015. Sequences with 
distance-based similarity of at least 97% were assigned the same OTU 
(operational taxonomic unit) and representative OTUs were classified using a 
modifiedfied Greengenes reference database (188).  
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2.4.5.  Tissue preparation for histology analysis. Intestinal tissues with 
luminal contents were carefully excised and fixed in freshly made nonaqueous 
Methacarn solution (60% methanol, 30% chloroform and 10% glacial acetic 
acid) as previously described (62,189) for 6 hours at 4oC. Tissues were 
washed in 70% ethanol, processed with Leica ASP6025 processor (Leica 
Microsystems) and paraffin-embedded by standard techniques. 5-μm sections 
were baked at 56oC for 1 hour prior to staining. 
 
2.4.6.  Fluorescence in-situ hybridization (FISH). The hybridization method 
was adapted from Swidsinski et al., 2005 and Vaishnava at el., 2011. Briefly, 
tissue sections were deparaffinized with xylene (twice, 10 min each) and 
rehydrated through an ethanol gradient (95%, 10 min; 90%, 10 min) to water. 
Sections were incubated with a universal bacterial probe directed against the 
16S rRNA gene or with probes specific to K. pneumoniae and Enterococcus at 
50oC for 3 hours. Probes were diluted to 5ng/μl in 0.9M NaCl, 20mM Tris-HCl 
at pH7.2 and 0.1% SDS prior to use. Sections were later washed twice in 0.9M 
NaCl, 20mM Tris-HCl at pH7.2 (wash buffer) for 10 min and counterstained 
with Hoechst (1:3000 in wash buffer) for nuclear staining. The following FISH 
probes were used: universal bacterial probe EUB338: [Cy3]-
GCTGCCTCCCGTAGGAGT-[AmC7~Q+Cy3es] (190). K. pneumoniae-specific 
probe Kpn: [Cy3]-CCTACACACCAGCGTGCC-[ AmC7~Q+Cy3es] (probe base 
accession number 00352,  (191)); Enterococcus-specific probe 
Enfm93:[AminoC6+Alexa488]-GCCACTCCTCTTTTTCCGG 
[AmC7~Q+Alexa488] (192).  
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2.4.7.  Muc2 immunofluorescence. Muc2 immunostaining was performed as 
previously described (63,175) with some modifications. Briefly, deparaffinized 
sections were incubated in 0.9M NaCl, 20mM Tris-HCl at pH7.2 and 0.1% 
SDS at 50oC for 3 hours, rinsed in PBS and blocked with 5% goat serum in 
PBS for 30 min at room temperature to minimize non-specific binding. 
Sections were then washed in PBS for 10 min prior to overnight incubation at 
4oC with an anti-Muc2 rabbit polyclonal antibody (H300, Santa Cruz; 1:200 in 
PBS) (193). Following incubation with primary antibody, tissues were washed 
3 times in PBS for 10 min and incubated with goat-anti-rabbit Alexa 488 
secondary antibody (Life Technologies, 1:1000 in PBS) for 1 hour at room 
temperature. Sections were washed twice in PBS for 10 min and 
counterstained with Hoechst (1:3000 in PBS). For FISH-Muc2 dual staining, 
sections were briefly rinsed in wash buffer after FISH hybridization and 
incubated directly with the anti-Muc2 primary antibody diluted in wash buffer. 
Incubation with secondary antibody was carried out at 4oC for 2 hours. A 
single 10 min PBS wash was performed after incubation with the primary and 
secondary antibodies before Hoechst nuclear staining and mounting with 
Mowiol solution. 
 
2.4.8.  Microscopy. Images were acquired with a Leica TCS SP5-II upright 
confocal microscope using a 63x oil immersion lens (NA 1.4, HCX PL APO) 
with or without digital zoom as a series of short Z-stacks. Maximum intensity 
projection processing of Z-stacks was done in Fiji (ImageJ) software. Mucus 
layer thickness was measured using the Leica distance measurement tool 
(LASAF).  The width of the inner mucus layer was determined by the average 
of 4 measurements per field with 4 fields measured per section. Whole tissue 
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images were digitally scanned using the Zeiss Mirax Desk Scanner with 
20x/0.8NA objective. Bacterial distance analysis was performed on colon 
images taken at 63x magnification with a 4x digital zoom by determining the 
XY coordinates of each bacterial cell in MetaMorph (Molecular Devices) 
software and measuring the distance from their center. For quantification of 
bacterial density and invasion into the mucus layer, whole tissue cross-
sections were tile scanned in short Z-stacks using an inverted laser scanning 
confocal Zeiss LSM 5-Live microscope at 63x magnification. For bacterial 
quantification, a threshold based on the RGB color combination and intensity 
of each bacterial species was generated with the color thresholding option in 
MetaMorph. Thresholded objects of 1μm in size were counted as a single 
bacterial cell with MetaMorph’s integrated morphometric analysis tool.  
 
2.4.9.  Statistics. The Mann-Whitney test was used for statistical analysis of 
intestinal CFU as well as image-based quantification of bacterial distance, 
density and infiltration into the mucus layer. Differences in mucus layer 
thickness were analyzed with the unpaired Student t test.  All statistical tests 
were performed using the Graph-Pad Prism software package (version 6.0). P 
values less than 0.05 were considered to be significant. 
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CHAPTER 3 
 
SPECIFIC BACTERIAL SPECIES CONFER COMMUNITY-WIDE ANTIBIOTIC 
RESISTANCE IN THE INTESTINE FOLLOWING LONG-TERM ANTIBIOTIC 
EXPOSURE 
 
3.1. INTRODUCTION 
Antibiotic administration can result in drastic changes to the intestinal 
microbiota that may compromise various aspects of gut function including 
protection against pathogen growth, a process known as colonization 
resistance (168). The extent by which antimicrobial agents disrupt the 
intestinal microbial ecosystem depends largely on the type of antibiotic used 
and the course of therapy. This was evidenced in recent infection studies 
where mice on a 3-day course of either ampicillin or enrofloxacin regained 
colonization resistance against Clostridium difficile as early as one day after 
antibiotic treatment, whereas mice treated with metronidazole and vancomycin 
or a single dose of clindamycin remained susceptible to infection for up to two 
to three weeks (145,154,194). Although re-establishment of colonization 
resistance suggests the return of key bacterial species, for the most part, the 
recovered microbiota does not resemble the former, pre-antibiotic, state. 
Despite regaining resistance to infection, clindamycin-treated mice exhibited 
decreased bacterial diversity that lasted for at least four weeks post treatment  
(154). In humans, a 7-day clindamycin course led to a dramatic reduction in 
the diversity of Bacteroides spp. that persisted even two years after cessation 
of antibiotic therapy (195,196). Similarly, treatment with ciprofloxacin 
decreased the overall bacterial diversity and despite the return of a substantial 
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portion of the microbiota four weeks following antibiotic administration, some 
Clostridiales members did not reappear (197). In addition, some antibiotic 
perturbations may persist and shift the microbiota to an alternative stable state 
in some individuals as a result of repeated clindamycin use (153). 
 Although these studies have shed considerable light on the long-term 
effects of short-course antibiotic therapy, the impact of prolonged antibiotic 
use on the composition of the microbiota and the stabilization of resistant 
strains is not well defined. Even after a short course on clindamycin, 
clindamycin-resistant Bacteroides spp. harboring erythromycin-resistant 
methylase (erm) genes were detected two years after treatment (195), while in 
a separate study, levels of erm genes remained significantly high even four 
years post treatment (198). These findings are consistent with the idea that the 
gastrointestinal tract serves as a reservoir for antibiotic-resistant genes  
(199,200) and may seem alarming given the increase in multidrug-resistant 
nosocomial pathogens (201). Nevertheless, the selection of antibiotic-resistant 
strains may confer a benefit to the entire microbial community when faced with 
continued antibiotic pressure. This benefit may come in the form of antibiotic-
degrading enzymes released into the environment or factors that can increase 
overall bacterial fitness (202,203). Therefore, although persistent antibiotic 
treatment can be potentially detrimental, it can also push the microbiota to 
evolve mechanisms of resistance without compromising function.   
 In this study, we describe and characterize a murine microbiota that 
developed resistance as a result of ongoing treatment with amoxicillin 
(ampicillin) and clavulanic acid for longer than a decade. We found that this 
microbiota, despite differing markedly from antibiotic-naive intestinal 
populations, exhibits a high degree of microbial diversity and functionality as 
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demonstrated by the preservation of distinct aspects of gut homeostasis, 
including colonization resistance against the opportunistic pathogen 
vancomycin-resistant Enterococcus. Furthermore, we identified a small 
fraction composed of specific members of the Parabacteroides and 
Bacteroides genera responsible for conferring population-wide antibiotic 
resistance through the production of β-lactamases. Our findings constitute an 
example of the remarkable adaptation capacity of the microbiota and provide 
evidence that long-term antibiotic exposure can result in collective antibiotic 
tolerance in the gastrointestinal tract, an event that proved crucial for the 
maintenance of normal intestinal function. 
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3.2. RESULTS 
 
3.2.1.  Long-term antibiotic therapy leads to the emergence of a unique 
and functional antibiotic-resistant gut microbiota  
The myeloid differentiation factor 88 (MyD88) is a critical signaling component 
of the innate immune system (204). As such, mice lacking MyD88 (MyD88-/-) 
are highly susceptible to infection and exhibit high rates of infection-related 
mortality (205). To prevent this, generations of MyD88-/- mice were 
continuously treated with a combination of amoxicillin/ampicillin (β-lactam 
antibiotic) and clavulanic acid (β-lactamase inhibitor) in their drinking water for 
over 15 years, which resulted in the development of an ampicillin/clavulanic 
acid-resistant microbiota.  
Taxonomic comparison of the fecal microbiota of MyD88-/- mice and 
C57BL/6 mice from Jackson laboratories, which carry an antibiotic-sensitive 
microbiota, showed similar proportions of Firmicutes and Bacteroidetes, the 
two dominant bacterial phyla, in MyD88-/- mice whereas 75% of the total 
bacterial population in C57BL/6 mice belonged to the Firmicutes (Figure 3.1A-
B). Although we found bacterial families (namely, Clostridiaceae, 
Ruminococcaceae, S24-7 and Lachnospiraceae) previously associated with a 
healthy microbiota (206) and that are often lost following antibiotic treatment  
(14,194) represented in both mouse groups, S24-7 was the dominant family in 
MyD88-/- mice at 40% relative abundance compared to 5-10% in C57BL/6 
animals. Conversely, over 50% of the C57BL/6 microbiota corresponded to the 
Clostridiaceae family, which was present at 15% abundance in MyD88-/- mice 
(Figure 3.1A).Finally, other bacterial families such as the Erysipelotrichiaceae, 
Bacteroidaceae, Prevotellaceae, Alcaligenaceae and Verrucomicrobiaceae 
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were found associated with MyD88-/-, but not C57BL/6, animals. (Figure 
3.1A). Despite these differences, MyD88-/- and C57BL/6 mice exhibited 
comparable bacterial diversity as measured by the inverse Simpson index 
(Figure 3.1C). However, the ileal compartment was significantly more diverse 
in MyD88-/- animals where, similar to the large intestine, S24-7 was the 
dominant family followed by Alcaligenaceae and Lachnospiraceae whereas 
the Lactobacillaceae and Clostridiaceae families were, for the most part, the 
major components of the C57BL/6 ileal microbiota (Supplementary Figure 
3.1A-B).  
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Figure 3.1. Taxonomic comparison between an antibiotic-tolerant and an 
antibiotic-sensitive microbiota. (A) Fecal microbiota composition of MyD88-/- and 
C57BL/6 mice. Each stacked bar corresponds to an individual mouse. OTUs at 
>0.01% relative abundance are shown. (B) Relative abundance of Firmicutes and 
Bacteroidetes OTUs. (C) Fecal microbiota alpha diversity. ns, non-significant by the 
Student’s t test. n = 4 per group.
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Analysis at the operational taxonomical unit (OTU) level in all intestinal 
compartments (ileum, cecum and feces) revealed that only 5% of all OTUs 
present at 0.1% abundance or higher were shared between MyD88-/- and 
C57BL/6 mice while 75-85% were unique to either mouse group (Figure 
3.2A). Specifically, MyD88-/- mice harbored Bacteroides sartorii, 
Parabacteroides distasonis and multiple S24-7 OTUs within the Bacteroidia 
class while the Clostridia class consisted mainly of cluster XIVa members 
Clostridium bolteae and Blautia producta in addition to several 
uncharacterized Clostridium spp. (Figure 3.2B) Of note, these bacterial 
groups have been reported to be present in the microbiota of healthy 
individuals but were not detected in C57BL/6 animals (23,207). Our analyses 
demonstrate that at the species level, the composition of the MyD88-/- 
microbiota differs almost completely from that of C57BL/6 Jackson mice.   
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3.2.2.  Transplantation of an antibiotic-resistant microbiota restores 
intestinal homeostasis in the presence of antibiotics 
We investigated whether the ampicillin-resistant flora, which we will refer to as 
ARF from here on, harbored by MyD88-/- mice could prevent the deleterious 
effects of antibiotic treatment and restore normal intestinal function. To this 
end, we subjected C57BL/6 mice to a 2-week course of ampicillin in the 
drinking water and administered three daily doses of fecal ARF beginning 24 
hours after the initiation of antibiotic treatment (Figure 3.3A). In line with 
previous evidence (14), we observed significantly reduced bacterial density as 
early as one day after ampicillin administration prior to any transplant (Figures 
3.3B, Untreated vs. Amp). Nevertheless, we detected a 3-log increase in 16S 
copy numbers immediately after the last ARF dose (day 4 post ampicillin) all 
the way through day 14, demonstrating that transplant with ARF was able to 
bring total bacterial DNA load back to initial, pre-antibiotic, levels even after 2 
weeks of ampicillin treatment (Figure 3.3B). Supporting this, we found that on 
day 4 post ampicillin treatment the bacterial composition of transplanted mice 
was nearly identical to the ARF input and remained stable throughout the 
duration of the experiment whereas control mice were depleted of most 
bacterial groups following antibiotic treatment (Figure 3.3C).  
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Consistent with the reconstitution of a complex and diverse microbiota, 
cecum enlargement, a phenotype characteristic of antibiotic treatment due 
water accumulation in the lumen (208,209), was reversed in antibiotic-treated 
mice that received ARF transplants making the intestinal anatomy of these 
mice indistinguishable from that of antibiotic-naïve animals (Figure 3.4A). 
Furthermore, antibiotic-mediated depletion results in thinning of the colonic 
mucus layer and down-regulation of the antimicrobial protein RegIIIγ  
(69,157,176) which we also observed (Figures 3.4, Untreated vs. Amp). 
However, ampicillin-treated mice colonized with ARF exhibited an increase in 
mucus-producing goblet cells and consequently, restoration of the protective 
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fecal material from MyD88-/- mice were administered by oral gavage to ampicillin-treated 
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treatment (n = 5 mice per group per time point). Box plots show the median, 25th percentile and 
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and ****p>0.0001 by the Student’ t test. (C) Microbiota composition of ampicillin-treated mice 
that received ARF or that were not manipulated. Each stacked bar represents the average of 5 
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inner mucus layer as well as dense bacterial staining restricted to the luminal 
compartment (Figure 3.4B). Finally, we also observed a rescue in RegIIIγ 
protein levels in ARF-treated animals, suggesting that ARF reconstitution can 
reset the normal immune tone of the intestine (Figure 3.4C). Taken together, 
our findings provide an example of how continued antibiotic pressure can drive 
intestinal microbial communities to develop antibiotic resistance and retain 
their complexity in order to maintain gastrointestinal health. 
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Figure 3.4. ARF reconstitution prevents antibiotic-induced changes in intestinal 
homeostasis. (A) Differences in cecum size in antibiotic-naive, ampicillin-treated and 
ARF-reconstituted ampicillin-treated animals. (B) Visualization of the inner mucin layer 
(Muc2) and bacteria (16S rRNA gene) in colon cross-sections. All sections were 
counterstained with Hoechst dye to visualize nuclei. Original magnification, 63X. Scale 
bars, 10 μm. (C) Western blot analysis of protein extracts from the distal region of the 
small intestine with RegIIIγ-specific antiserum and anti - β-tubulin as a loading control. 
(A-C) Shown are representative images and samples from 5 mice per group. 
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3.2.3.  Efficacy of ARF bacteriotherapy against vancomycin-resistant 
Enterocococcus 
To expand our functional characterization studies, we assessed the ability of 
ARF to prevent and eliminate colonization by the nosocomial pathogen 
vancomycin-resistant Enterococcus (VRE). To examine whether ARF could 
preserve colonization resistance against VRE in antibiotic-treated animals, we 
infected mice the day following the last of three ARF transplants, the earliest 
time-point at which we observed complete engraftment of ARF (Figures 
3.3C). While VRE had reached a density of 109 colony forming units (CFU) in 
the feces of PBS-treated mice starting at day 1 post infection (p.i.), VRE levels 
in ARF-treated mice were significantly lower on day 1 p.i (104 CFU) and 
became undetectable by day 3 p.i., demonstrating that ARF has the ability to 
re-establish colonization resistance despite ongoing antibiotic treatment 
(Figure 3.5A). Remarkably, fecal extracts from ARF-treated animals were also 
able to suppress VRE growth ex vivo, suggesting that colonization resistance 
against VRE is mediated exclusively by the intestinal microbiota and 
independent of the host (Figure 3.5B). 
Murine models have shown that once VRE has colonized the intestine, 
it can persist for as long as two months even in the absence of antibiotics and 
clearance can only be achieved through transplantation with a healthy and 
diverse fecal microbiota (14,159,176). We tested the potential of ARF to 
eliminate established VRE by administering three consecutive ARF doses 
beginning 3 days following infection with VRE, at which point VRE becomes 
stable in the intestine (Chapter 2, Supplementary Figure 1B). Prior to 
treatment, VRE burden was similarly high in all mice and remained elevated in 
mice that went on to receive PBS instead of ARF whereas ARF-treated 
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animals showed a progressive reduction in VRE levels with clearance by day 
15 post ARF administration (Figure 3.5C). The rate of VRE clearance with 
ARF mirrors the efficacy obtained with fecal transplants from C57BL/6 
Jackson mice (159). Altogether, our findings showing that ARF can preserve 
intestinal homeostasis suggests that despite being compositionally different, 
ARF exerts the same protective effect as the C57BL/6 microbiota.         
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3.2.4.  Collective antibiotic resistance is mediated by a few β-lactamase-
producing bacterial strains within ARF 
Evidence from in vitro studies has demonstrated that bacterial populations 
may owe their ability to survive antibiotic pressure to minor members with the 
capacity to resist killing by antibiotics. Although this effect can be direct, as in 
production of antibiotic-degrading enzymes (i.e. β-lactamases), resistant cells 
can also produce factors such as the cell-signaling molecule indole that allow 
their susceptible counterparts to withstand antibiotic stress (203,210,211). 
These observations prompted us to investigate whether the antibiotic 
resistance capability of ARF was a collective rather than individual endeavor. 
To address this, we plated a 105-fold diluted suspension of fecal ARF on 
plates containing increasing concentrations of ampicillin ranging from 0 to 0.5 
mg/ml and examined the bacterial composition of each plate. We identified 
about 15 distinct bacterial on plates containing no ampicillin, which 
corresponded to about 20% of the biodiversity of ARF (Figure 3.6A-B). 
However, this diversity was lost at ampicillin concentrations as low as 0.01 
mg/ml at which mostly Parabacteroides distasonis, Clostridium bolteae and 
some Bacteroides spp. (B. sartorii, B. uniformis, B. acidifaciens) were able to 
grow. The number of unique organisms was further reduced at higher 
ampicillin concentrations where an enrichment for P. distasonis, B. sartorii and 
B. uniformis was observed (Figure 3.6A-B).  
 We hypothesized that inoculation of bacteria grown under non-selective 
conditions into antibiotic-treated mice would lead to expansion of the 
ampicillin-resistant fraction and reduction of the ampicillin-sensitive one. 
Following our transplantation model, we administered mice three daily doses 
of the contents from each plate (Input) beginning on their second day of 
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ampicillin treatment and collected fecal samples 24 hours after the last dose 
(Output). Almost all Input bacteria underwent shifts in vivo but the ampicillin-
sensitive fraction remained a significant portion of the population. In addition, a 
trend towards higher C. bolteae relative abundance in the output was 
observed for all the ampicillin concentrations that supported C. bolteae growth 
while P. distasonis and B. sartorii, which constituted over 90% of bacteria 
found on plates containing ampicillin concentrations of 0.1 mg/ml and higher 
remained the predominant populations in vivo (Figure 3.6C). Furthermore, we 
assessed whether the loss of ampicillin-sensitive bacteria would impact 
colonization resistance against VRE as a measure of normal intestinal 
function. We infected ampicillin-treated mice that had been inoculated with the 
different plate cultures and found that colonization resistance had been 
abrogated in all mice that had received bacteria grown under ampicillin 
selection, regardless of concentration (Figure 3.6D).  
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Resistance to β-lactams is primarily due to degradation of the β-lactam 
ring by β-lactamases (212). Using the chromogenic cephalosporin substrate, 
which changes from yellow to red when cleaved (213), we observed β-
lactamase activity in fecal samples from MyD88-/- but not C57BL/6 mice 
(Figure 3.7A). Consistent with the results of our ampicillin susceptibility test, 
cultures from P. distasonis, B. sartorii and B. acidifaciens isolated from ARF 
exhibited strong β-lactamase activity whereas none was detected in cultures 
from a Blautia producta isolate (Figure 3.7B). Our observations demonstrate 
that culturable anaerobic bacteria comprising roughly 5% of the bacterial 
population in ARF are highly resistant to ampicillin and produce ampicillin-
degrading enzymes that allow the survival of the ampicillin-sensitive fraction 
responsible for providing colonization resistance.  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
C57BL/6
MyD88-/-
- + P.D. B.S. B.A. B.P
A
B
Figure 3.7. β-lactamase production by ARF and select isolates. β-lactamase 
activity of (A) fecal samples from MyD88-/- and C57BL/6 mice and (B) isolates 
cultured from MyD88-/- feces. P.D. Parabacteroides distasonis; B.S., Bacteroides 
sartorii; B.A., Bacteroides acidifaciens; B.P., Blautia producta; - , negative control 
(PBS); + , positive control (AmpR E.coli DH5α).
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3.3. DISCUSSION 
Although antibiotics have proved critical in the fight against infection, they also 
exert widespread collateral damage to the body’s microbiota. Even short 
courses of antibiotic therapy can induce long-lasting perturbations in the gut 
microbiota including loss of bacterial species and selection for antibiotic-
resistant strains. This poses a serious health problem since loss of 
colonization resistance resulting from antimicrobial treatment can promote the 
intestinal expansion of disease-causing drug-resistant organisms (14,82,158). 
Because of this, it may seem counterintuitive to envision positive outcomes 
following long-term antibiotic therapy. Our study is, to the best of our 
knowledge, the first to demonstrate that continuous antibiotic exposure of 
laboratory mice for generations spanning 10+ years can result in a unique, 
complex and functional antibiotic-resistant microbiota. In our laboratory, 
treatment of MyD88-/- animals with amoxicillin and clavulanic acid was used as 
a measure to prevent spontaneous infection. Clavulanic acid enhances the 
efficacy of amoxicillin by inactivating β-lactamases produced by amoxicillin-
resistant organisms and are often used in combination during antibiotic 
therapy (214). Since fecal samples were not collected prior and during 
antibiotic exposure, we cannot definitively know when and how resistance took 
place, how the MyD88-/- microbiota shifted during 15 years of antibiotic therapy 
and whether a reservoir for ampicillin-resistant strains existed prior to therapy. 
Despite these unknowns, our findings reveal that the MyD88-/- microbiota is 
composed of a diverse bacterial community that it’s characterized by an 
overabundance of S24-7 (Barnesiella) species and low abundance of 
Clostridia. Although several studies have linked microbiota composition to host 
genotype, previous work from our laboratory revealed that compositional 
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differences among mice lacking distinct arms of innate immunity are a 
consequence of long-term breeding in isolation and vertical transmission 
rather than genetic mutation (78). Therefore, the unique microbiota of MyD88-/- 
animals is largely a result of husbandry conditions (i.e. exposure to 
antimicrobial agents) and not MyD88 deficiency. 
The most striking aspect of our study was the discovery that after 15 
years of antibiotic treatment, most of the MyD88-/- microbiota had remained 
susceptible to the antibiotic whereas a minor fraction was highly resistant. This 
phenomenon was termed ‘bacterial cheating’ by Lee et al. in a study showing 
that over time, E.coli cultures were able to withstand high norfloxacin 
concentrations even though individual clones were vulnerable to the antibiotic  
(203). In these scenarios, antibiotic-sensitive bacteria can be thought of as 
‘cheaters’ since they benefit from the activity of antibiotic-resistant bacteria 
and may grow faster than the resistant population once the antibiotic has been 
inactivated (202,210). Although charity and cheating can be explored in great 
detail in homogenous populations, the complexity of the microbiota makes 
these processes difficult to study in vivo. We overcame this problem by 
culturing the MyD88-/- microbiota under rich, anaerobic conditions in the 
presence of increasing ampicillin concentrations. By doing this, we loss most 
of the diversity found on ampicillin-negative cultures suggesting that the 
majority of bacteria that make up the MyD88-/- microbiota cannot survive 
antibiotic stress in isolation.  
The concept of charity and/or cheating implies that one population is 
responsible for the production of ‘public goods’ that other bacteria can benefit 
from without reciprocating. In this scenario, β-lactamases produced by 
Bacteroides and Parabacteroides spp. to protect themselves from antibiotic 
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toxicity became an asset to the entire bacterial community. These organisms, 
although normally present in small frequencies, can colonize the murine 
intestinal tract at densities comparable to that of in-vitro cultures indicating that 
the presence of the antibiotic-sensitive fraction is not required for their survival 
or maintenance. Based on these observations, it appears that in our model 
coexistence is a one-way street involving the degradation of ampicillin in the 
intestinal lumen by hydrolytic enzymes produced by a subset of the 
population, a process that, inadvertently but efficiently, ensures the survival of 
the remainder microbiota. One explanation for the limited number of ampicillin-
resistant species despite the length of treatment is that antibiotic-resistant 
genes were present in these bacterial groups even before therapy. While 
resistance to ampicillin/amoxicillin is a common occurrence among 
Bacteroides and Parabacteroides, resistance to β-lactamase inhibitors such 
as clavulanic acid is rare (215-217). Nevertheless, administration of amoxicillin 
in combination with β-lactamase-inactivating agents has been significantly 
associated with the emergence of resistant strains in the clinic (218,219). 
Therefore, it is possible that Parabacteroides and Bacteroides spp. harbored 
ampicillin-resistance genes at the time of antibiotic treatment but addition of 
clavulanic acid selected for mutants that could grow in the presence of the β-
lactamase inhibitor. In this way, continued antibiotic therapy may have pushed 
these bacterial groups to become increasingly resistant and produce large 
amounts of β-lactamases lowering the ampicillin concentration in the intestinal 
lumen, an event that may have taken place at the initial stages of treatment 
and prevented the development of resistance in other anaerobic organisms. 
The finding that within a community of hundreds of species Bacteroides and 
Parabacteroides are the only highly resistant strains after 15 years of antibiotic 
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treatment is contrary to the idea that the presence of antibiotic-resistant 
bacteria enhance horizontal transmission of antibiotic determinants the 
intestine (220). Although horizontal gene transfer is an important clinical and 
microbiological problem, most antibiotic-resistance genes in Bacteroides and 
Parabacteroides are chromosomally encoded (216) and their location may 
have prevented resistance from spreading to other organisms within the 
community.  
Despite the difference in ampicillin susceptibility we show that by 
adoptively transferring suspensions from MyD88-/- stool samples into mice 
undergoing ampicillin therapy, many of the adverse effects caused by 
ampicillin including enlargement of the cecum, decreased production of 
mucins and antimicrobial peptides and loss of colonization resistance were 
reversed in all animals that received fecal transplants. Importantly, our findings 
demonstrate that the ampicillin-sensitive fraction is the one exerting such 
recovery, supporting the idea that the role of resistant Bacteroides and 
Parabacteroides spp. in this process is the production of ampicillin-degrading 
enzymes that keep the rest of the microbiota alive. This observation implies 
that administration of β-lactamase-producing strains during antibiotic treatment 
may help protect the intestinal microbiota and preserve gut function. In fact, 
studies have shown that oral administration of β-lactamase enzymes, a β-
lactamase-containing microbiota, or a cephalosporinase-producing strain of 
Bacteroides thethaiotamicron can preserve colonization resistance in 
otherwise susceptible animals (221-223). These findings together with ours 
suggest that administration of β-lactamase-producing bacteria may have 
important clinical implications and. On the one hand, the presence of β-
lactamase-producing Bacteroides may preserve the microbiota and many of its 
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functions in the face of antibiotic treatment. Such prophylactic treatments 
would provide a mechanism by which bloodstream infections could be treated 
with antibiotics while sparing the intestinal microbiota except in situations 
when non-β-lactam antibiotics are used. On the other hand, there is the 
potential for these organisms to become pathogenic in which case their 
treatment may be limited given their level of resistance. In addition, ampicillin-
sensitive infectious agents may take advantage of the detoxification of the 
intestinal lumen and potentially cause disease. 
In conclusion, our study shows that years of ongoing therapy with 
combination of a β-lactam agent with a β-lactamase inhibitor resulted in the 
development of a complex, functional and stable microbiota capable of 
withstanding antibiotic pressure collectively but not independently. Whether 
this can occur in patients undergoing long-term antibiotic therapy is unknown. 
The fact that our mice were subjected to antibiotic treatment for multiple 
generations makes it unlikely that the same level of resistance, diversity and 
functionality may arise in humans. Nonetheless, the generation of a bigger 
pool of antibiotic-resistant strains is a possibility. In our model, collective 
antibiotic resistance resulted from the activity of a small percentage of 
resistant bacteria comprising species of the Bacteroides and Parabacteroides 
genera that provided β-lactamase-mediated protection of the susceptible 
bacterial compartment and in this way, helped maintain normal gut function.  
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3.4. MATERIALS AND METHODS 
 
3.4.1.  Mouse strains, adoptive transfer and VRE infection. 16 week-old 
MyD88-/- male mice from our facility and age, gender-matched C57BL/6 mice 
purchased from Jackson Laboratories were used for taxonomic comparisons. 
For experiments involving microbiota transplantation and VRE infection, 6-8 
week old female mice from Jackson Labs were treated with 0.5g/L ampicillin 
(Fisher) in their drinking water made fresh every 4 days. Fecal transplants 
were prepared by resuspending fresh stool pellets from a MyD88-/- donor in 1 
ml pre-reduced PBS. 200μl of this suspension was administered into mice by 
oral gavage daily for 3 days. For VRE infection, 5x104 CFU of vancomycin-
resistant Enterococcus faecium (ATCC 700221) were administered to mice by 
oral gavage in a 200μl volume. Mice were single-housed at the time of 
infection and kept on ampicillin until the end of the experiment. For VRE 
quantification, tenfold dilutions of pre-weighed fecal samples resuspended in 
PBS were plated on Difco Enterococcosel agar (supplemented with 8 μg/ml 
vancomycin; Novaplus and 100 μg/ml streptomycin; Fisher). 
 
3.4.2. Bacterial DNA extraction. Intestinal samples were frozen in a dry 
ice/ethanol slurry immediately after collection and stored at −80 °C. Samples 
were resuspended in 500 μl of an extraction buffer (200 mM Tris pH 
8.0/200 mM NaCl/20 mM EDTA), 200 μl of 20% SDS, 500 μl of 
phenol:chloroform:isoamyl alcohol (24:24:1) and 500 μl of 0.1-mm diameter 
zirconia/silica beads (BioSpec Products). Cells were lysed by mechanical 
disruption using a bead beater (2 min). DNA was extracted using a 
phenol/chloroform/isoamyl solution twice and precipitated with ethanol and 
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sodium acetate. DNA was resuspended in 200 μl of TE buffer containing 
100 μg/ml RNase, purified with QIAmp Mini Spin Columns (Qiagen) and eluted 
in 100 μl water.   
 
3.4.3.  16S rRNA amplification, multiparallel sequencing and sequence 
analysis. The V4–V5 region of the 16S rRNA gene was amplified and 
sequenced on an Illumina MiSeq platform using primers 563F (59-nnnnnnnn-N
NNNNNNNNNNN-AYTGGGYDTAAAGN G-39) and 926R (59-nnnnnnnn-NNN
NNNNNNNNN-CCGTCAATTYHTTTR AGT-39). The PCR reaction consisted 
of 50 ng of purified DNA, 0.2 mM dNTPs, 1.5 μM MgCl2, 1.25 U Platinum 
TaqDNA polymerase, 2.5 μl of 10X PCR buffer and 0.2 μM of each primer. A 
unique 12-base Golay barcode (Ns) preceded the primers for sample 
identification after pooling amplicons. One to eight additional nucleotides were 
added before the barcode to offset the sequencing of the primers. The cycling 
conditions were: 94 °C (3 min), 27 cycles of 94 °C (50 s), 51 °C (30 s) and 72 °C 
(1 min) followed by a final elongation step at 72 °C (5 min). Replicate PCRs 
were pooled and purified using the Qiaquick PCR Purification Kit (Qiagen) and 
Qiagen MinElute PCR Purification Kit. PCR products were quantified using the 
Illumina TruSeq Sample Preparation procedure and combined at equimolar 
amounts before Illumina barcodes and adaptors were added. The completed 
library was sequenced on an Ilumina Miseq platform as per Illumina 
specifications. Sequence analysis was performed using the mothur pipeline 
(version 1.33.3). Sequences were aligned using the Silva reference alignment 
as a template and chimeric sequences were eliminated using UCHIME (224). 
Sequences with a distance-based similarity of ≥97% were binned into OTUs 
using the furthest-neighbour algorithm. OTUs were classified using a modified 
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Greengenes 16S rRNA reference database [45]. OTU-based biodiversity was 
calculated by Inverse Simpson index. OTUs at relative abundance 
>0.01% were plotted. 
 
3.4.4.  Quantification of bacterial density by qPCR. Copies of the 16S 
rRNA gene were determined by performing quantitative PCR on total DNA 
extracted from fecal samples using primers specific to the V4 region of the 
16S gene, 517F (5’-GCCAGCAG CCGCGGTAA-3’) and 798R (5’-
AGGGTATCTAATCCT-3’), at 0.2 μM concentration with the DyNAmo SYBR 
green RT-PCR kit (Finnzymes). Standard curves were prepared by serial 
dilution of the PCR blunt vector (Invitrogen) containing a single copy of the 
16S rRNA gene. The cycling protocol was: 95 oC for 10 min, followed by 40 
cycles of 95 oC for 30 s, 52 oC for 30 s, and 72 oC for 1 min. 
 
3.4.5. FISH and Muc2 Immunofluorescence. Tissues were fixed in 
Methacarn solution (60% methanol, 30% chloroform and 10% acetic acid) to 
preserve intestinal architecture. Co-staining for bacteria and Muc2 was 
performed as previously described (175) using the universal EUB338 bacterial 
probe and anti-Muc2 rabbit polyclonal antibody (H300, Santa Cruz). Image 
acquisition was performed with a Leica TCS SP5-II upright confocal 
microscope using a 63x oil immersion lens as a series of short Z-stacks. Fiji 
(ImageJ) software was used for maximum intensity Z-stack projection. 
 
3.4.6.  Western blot analysis. A 2-cm segment from the distal portion of the 
small intestine was excised and stored in RNA stabilization solution (RNAlater) 
at 4oC prior to homogenization with Trizol reagent (Invitrogen). Total protein 
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was extracted according to the manufacturer’s specifications and resuspended 
in a solution of 8 mol/L urea, 1% sodium dodecyl sulfate (SDS) and 0.15 mol/L 
Tris-HCl at pH 7.5. Equal amounts of protein were denatured, loaded onto a 4-
12% SDS-polyacrylamide electrophoresis gel (Nupage Bis-Tris gel, Invitrogen) 
and transferred to a nitrocellulose membrane. Protein blots were incubated 
with rabbit polyclonal RegIIIγ specific-antiserum and mouse anti-β-tubulin 
(Santa Cruz Biotechnology) antibodies, followed by horseradish peroxidase-
conjugated anti-rabbit (GE Healthcare) and anti-mouse (Santa Cruz 
technology) antibodies.Protein bands were detected using chemiluminescence 
(GE Healthcare). 
 
3.4.7.  Ex vivo VRE suppression assay. Fecal samples from C57BL/6 
ampicillin-treated mice that received 3 consecutive doses of ARF or PBS were 
collected, transferred to an anaerobic chamber and resuspended in reduced 
PBS at a concentration of 25mg/ml. VRE (5x103 CFU) or PBS was added to 
each sample and incubated at 37 oC anaerobically. VRE growth was assessed 
16-24 hours later by plating on selective media. 
 
3.4.8.  β-lactamase detection assay. Fecal pellets from MyD88-/- and 
C57BL/6 animals were collected and resuspended in PBS at 25mg/ml. 
Samples were left undisturbed for 5 minutes to allow particulate matter to 
sediment. 100μl of the suspension was pipetted into a 96-well plate with 50μl 
of nitrocefin (0.2 mg/ml, Fisher) and incubated for 30 minutes at room 
temperature while protected from light. For detection of β-lactamase activity 
from individual isolates, 100μl from a 3-day anaerobic culture corresponding to 
106 CFU was used.  
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3.4.9.  ARF cultures and ampicillin susceptibility assay. Fecal samples 
from MyD88-/- mice were collected, transferred immediately to an anaerobic 
chamber, resuspended in 1 ml pre-reduced PBS. Fecal suspensions were 
titered by culturing 100μl from 10-fold serial dilutions on Columbia agar plates 
supplemented with 5% sheep blood and ampicillin concentrations in the 0-
0.5mg/ml range. Plate cultures were incubated anaerobically at 37oC for 3-5 
days, bacterial colonies were scraped off the plates and resuspended in 5 ml 
pre-reduced PBS. 500μl of culture suspensions were removed for sequencing 
analysis and stored at -80oC. For inocula preparation, glycerol was added to 
the remaining cultures at a final concentration of 15% and aliquoted before 
freezing at -80oC.  
 
3.4.10.  Statistics. All statistical tests were performed with the unpaired 
Student’s t test using the Graph-Pad Prism software package (version 6.0).  
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CHAPTER 4 
 
DEFINED BACTERIOTHERAPY RESTORES RESISTANCE AGAINST 
VANCOMYCIN-RESISTANT ENTEROCOCCUS 
 
4.1. INTRODUCTION 
For many years, the prevention and treatment of nosocomial infections have 
relied heavily on the use of antimicrobial agents with varying spectra of 
activity. Despite the effectiveness of antibiotics in the treatment of infection  
(167), this practice has become increasingly less popular due to their impact 
on non-target, intestinal commensals and the potential for the expansion of 
multi-drug resistance pathogens (145). For instance, treatment of Clostridium 
difficile-infection (CDI) with metronidazole or vancomycin increases the risk for 
colonization by vancomycin-resistant Enterococcus and multi-drug resistant 
Enterobacteriaceae in humans and laboratory animals (194,225). Increased 
susceptibility to infection and colonization is a direct consequence of antibiotic-
mediated depletion of beneficial microbes whose role is to mediate resistance 
against pathogens (14,154,168). 
 The detrimental effects caused by antibiotics have accelerated the 
search for safer and more efficient ways to treat intestinal infections. A therapy 
that has had tremendous clinical success in the treatment of CDI is fecal 
microbiota transplantation (FMT), a method that involves the adoptive transfer 
of feces from a healthy donor into afflicted individuals by stool enemas, 
colonoscopy or duodenal administration (226). Compared to conventional 
antibiotic therapies where the rate of efficacy was only 23-31%, the rate of CDI 
resolution with FMT was 81% after a single naso-duodenal dose and 94% 
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after a second one (174) while in patients receiving FMT through colonoscopy, 
a 91% cure rate was achieved within 90 days post transplant (227). Although 
FMT is most commonly used for the treatment of CDI, a case report showed 
that it can also eliminate colonization by other nosocomial pathogens, 
including VRE (228). In fact, murine studies have shown that VRE can be 
effectively eliminated with fecal transplants from a healthy, antibiotic-naïve 
mouse (159,176) or as discussed in Chapter 3 of this dissertation, a diverse 
antibiotic-resistant flora.  
 Despite its efficacy, a major caveat of FMT is the transmission of 
pathogens (bacteria, fungi or viruses) that may be undetectable at the time of 
transplant or have yet to be identified (161,226). Such risks can be prevented 
by a more targeted approach involving the identification of specific bacterial 
strains that mediate resistance. Several groups have made progress in this 
area in the context of murine CDI. One group found that a member of the 
Lachnospiraceae family could reduce C. difficile burden 100-fold (229) while 
another showed that a mixture of 6 distinct bacterial strains reduced C. difficile 
to levels below detection 15 days post treatment (230). More recently, it was 
demonstrated that Clostridium scindens, a Clostridia species from cluster 
XIVa, can significantly reduce C. difficile expansion, an inhibitory effect that 
was enhanced when administered in combination with three other strains  
(145). Despite these promising findings, commensal bacteria responsible for 
resistance against other intestinal pathogens such as VRE remain to be 
identified.  
 To address this, we expanded our preliminary findings showing that a 
culturable fraction of an ampicillin-resistant flora (ARF) could prevent 
colonization by VRE (Chapter 3). Using the dilution method as a strategy to 
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induce variability in protection, we identified a community of bacteria that were 
significantly correlated with resistance. Resistance-associated strains were 
isolated, assembled into different consortia and adoptively transferred into 
antibiotic-treated mice. The results presented here revealed that a two-
bacteria consortium consisting of members of Clostridia cluster XIVa, 
Clostridium bolteae and Blautia producta, exert complete colonization 
resistance against VRE and eliminate established VRE colonization. 
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4.2. RESULTS 
 
4.2.1.  Select bacterial communities are associated with resistance to 
VRE 
Our previous findings that plate cultures from a 105-fold diluted ARF 
suspension provided full colonization resistance against VRE suggested that 
bacterial species responsible for VRE protection could be cultured in vitro 
under non-selective, anaerobic conditions. To identify resistance-associated 
organisms, we performed an additional 1/10 dilution of ARF to reduce 
community complexity further and generate variability in VRE protection. 
Compared to the 10-5 dilution, increased abundance levels of Bacteroides spp. 
and an unclassified Blautia OTU were recovered from the 10-6 dilution 
cultures. In addition, we detected slightly higher levels of OTUs belonging to 
the S24-7 family in the 10-6 dilution while other OTUs, including one 
corresponding to Clostridium hylemonae, were only present in the 10-5 dilution 
or undiluted ARF suspensions (Figure 4.1A). We harvested bacterial cultures 
from single 10-5 or 10-6 dilution plates, gavaged them into antibiotic-treated 
mice for three consecutive days beginning on the second day of ampicillin 
treatment and infected mice with VRE the day after the last bacterial or PBS 
dose. As shown previously, mice that received the 10-5-dilution cultures had 
undetectable VRE levels at day 3 p.i. whereas PBS-treated animals were 
densely colonized. Consistent with our predictions, variability in colonization 
was observed in mice gavaged with cultures from the 10-6 dilution, suggesting 
the loss of key bacterial species (Figure 4.1B).  
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 As expected, antibiotic-treated mice that received PBS instead of a 
bacterial suspension exhibited markedly lower biodiversity than the pre-
antibiotic state. However, this reduction in diversity was significantly increased 
following administration of bacterial cultures from both the 10-5 and 10-6 
dilutions (Figure 4.2A). Low bacterial diversity increases the likelihood of 
intestinal infection and colonization (158,159). Although this was indeed the 
case for all PBS-treated animals, within the 10-6 dilution group colonization 
resistance was observed in mice harboring a microbiota less diverse than that 
of some susceptible mice (Figure 4.2B). The finding that low biodiversity does 
not always correlate with infection susceptibility was previously reported (145) 
and suggests that the presence of specific bacterial species, rather than the 
degree of diversity, is the determinant factor in preventing colonization. To 
identify candidate bacteria, we stratified mice from the 10-6 dilution group by 
their VRE density and plotted the abundance of the top 20 OTUs on a heat 
map (Figure 4.2C). While most OTUs were present in all resistant mice at 
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various frequencies, several of them including members of the Clostridia 
(Blautia spp., Oscillospira spp. and Clostridium bolteae), Mollicutes 
(Eubacterium dolichum), Bacteroidia (Bacteroides spp., S24-7 and 
Rikenellaceae families) and β-proteobacteria (Sutterella spp.) classes were 
undetectable in susceptible animals (Figure 4.2C). Of these, we identified 8 
bacterial OTUs that correlated significantly with resistance to VRE colonization 
according to the Spearman’s rank correlation test (Figure 4.2D). Importantly, 
the second OTU most strongly correlated with resistance was an unclassified 
strain from the S24-7 family also known as Barnesiella, confirming our 
previous findings that a Barnesiella-containing microbiota was significantly 
associated with VRE clearance (159). 
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4.2.2. Defined resistance-associated bacterial groups restore 
colonization resistance against VRE 
In order to isolate bacterial strains responsible for VRE protection, we picked 
250 colonies from 10-5 dilution plates, the highest dilution that was able to re-
establish resistance in all mice. Sanger sequencing and BLAST classification 
of the 16S rRNA gene of isolated colonies revealed the presence of at least 19 
distinct bacterial species belonging to the Bacteroidaceae, Clostridiaceae, 
Porphyromonadaceae, Coriobacteriaceae, Rikenellaceae, Lachnospiraceae, 
unclassified_Clostridiales and Verrucomicrobiaceae families with considerable 
redundancy among isolates  (Table 4.1). To determine whether any of the 8 
resistance-associated OTUs were present in our library, we aligned Miseq and 
Sanger sequencing reads and found 100% sequence similarity between 4 
OTUs and some of our isolates, namely unclassified Blautia, Blautia producta, 
Clostridium bolteae and Eubacterium dolichum, whose 16S sequence was 
identical to that of isolates classified as Clostridium innocuum. Of note, we 
detected OTUs corresponding to Akkermansia muciniphila, Bacteroides 
sartorii and Parabacteroides distasonis at very high densities in susceptible 
and resistant animals alike (Figure 4.2C). These organisms are well known for 
their ability to digest complex polysaccharides, including mucin (172,231). In 
addition, we previously showed that B. sartorii and P. distasonis are highly 
resistant to ampicillin. Therefore, even though these OTUs did not reach 
statistical significance in our correlation analysis, we hypothesized that they 
could potentially play an important role in the establishment and maintenance 
of resistance-associated strains by providing a direct source of nutrients and 
inactivating ampicillin. 
 
	   97	  
 Using this rationale, we assembled a suspension of 7 ARF isolates: 
unclassified Blautia, B. producta, C. bolteae, E. dolichum, A. muciniphila, B. 
sartorii and P. distasonis. To examine the potential for this bacterial cocktail to 
restore colonization resistance during antibiotic treatment, we used our well-
described transplantation model and orally administered a mixture of the 7 
strains (7-mix) or PBS into mice for three consecutive days beginning on their 
second day of ampicillin, infected them with VRE the day following the last 
gavage dose and collected fecal samples 1, 3 and 6/8 days p.i to monitor 
colonization. Out of 10 mice that received the 7-mix, 8 had undetectable VRE 
levels as early as 1 day p.i. and 2 had a VRE burden of 106-108 that had 
decreased by 2-logs on day 6/8 p.i. whereas VRE levels in PBS-treated 
animals ranged between 108-1010 CFU at all time points p.i. (Figure 4.3A) 
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To assess the extent by which each strain in the 7-mix contributed to 
colonization resistance, we treated mice with mixtures containing all but one 
bacterium. We excluded A. muciniphila, E. dolichum, unclassified Blautia, C. 
bolteae or B. producta but kept P. distasonis and B. sartorii in every group for 
their ampicillin-degrading capacity. We found that exclusion of unclassified 
Blautia or E. dolichum did not impact the protection ability exerted by the 
remaining strains whereas an intermediate effect was observed in the absence 
of A. muciniphila (Figure 4.3B). Remarkably, complete loss of colonization 
resistance was observed in mice gavaged with bacterial mixtures deficient in 
C. bolteae or B. producta (Figure 4.3B). These findings indicated that within 
our 7 bacterial consortium, unclassified Blautia and E. dolichum were not 
directly involved in colonization resistance and were therefore excluded from 
future experiments, while on the other hand C. bolteae and B. producta 
appeared to be critical for the 7-mix protective effects against VRE. To further 
examine this, we treated mice with different combinations of the remaining 5 
strains and found that a combination of C. bolteae, B. producta, P. distasonis 
and B. sartorii was the smallest consortium that fully restored colonization 
resistance in antibiotic-treated animals (Figure 4.3C). Subsets from this 4-mix 
showed that mice colonized with P. distasonis and B. sartorii or C. bolteae and 
B. producta exhibited VRE levels comparable to that of control animals 
suggesting that the β-lactamase-producing strains do not, on their own, inhibit 
VRE colonization but are required for the survival of ampicillin-sensitive C. 
bolteae and B. producta (Figure 4.3C).  
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Importantly, the same protection pattern was observed in the distal 
portion of the small intestine (Supplementary Figure 4.1A). Finally, we show 
that neither C. bolteae nor B. producta is able to restore colonization 
resistance when administered individually even in the presence of P. 
distasonis and B sartorii, supporting the idea that both strains work together to 
suppress VRE growth (Figure 4.3C). Because ampicillin was administered 
throughout the duration of the experiment, it is unlikely that native bacteria 
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would reappear. However, a possibility exists that administration of the 4-mix 
may enhance the recovery of indigenous bacteria directly responsible for 
colonization resistance. To determine if this was indeed the case, we 
assessed the microbiota composition of mice colonized with the various 
bacterial consortia. Strikingly, we found that while PBS-treated mice were fully 
dominated with VRE, mice colonized with the 4-mix harbored only the 4 
administered bacteria with B. producta representing 30-70% of the total 
bacterial composition. While all 4 bacteria were detected in the feces, the 
small intestine consisted mostly of B. producta (65-98%) and C. bolteae (1-
35%) (Figure 4.3D and Supplementary Figure 4.1B). Similarly, the 
microbiota of mice colonized with the 5-mix consisted of the 5 input bacteria in 
addition to an unclassified Clostridium OTU which expanded considerably in 
the ileum. On the other hand and in agreement with our CFU data, mice 
colonized with P. distasonis and B. uniformis exhibited high VRE relative 
abundance levels in the stool while the ileum was completely dominated VRE 
(Figure 4.3D and Supplementary Figure 4.1B). These findings demonstrate 
that colonization with P. distasonis, B. sartorii, B. producta and C. bolteae 
directly provides full colonization resistance against VRE.  
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4.2.3.  Bacterial consortia prevent VRE growth ex vivo and in vitro 
We previously showed that ARF could inhibit VRE growth ex vivo as efficiently 
as in vivo (Chapter 3, Figure 3.4). Treatment with metronidazole, an antibiotic 
that specifically targets anaerobic bacteria, completely abrogated the inhibitory 
effect or ARF, an effect that was not observed with aminoglycosides 
(gentamicin, streptomycin) that have limited anaerobic coverage 
(Supplementary Figure 4.2A-B). Loss of ARF-mediated suppression was 
also observed with heat treatment of fecal samples prior to VRE inoculation 
(Supplementary Figure 4.2C). Together these data suggest that the 
anaerobic compartment is the one responsible for mediating colonization 
resistance against VRE and that anaerobes need to be alive to exert such 
effect, observations that are consistent with the results obtained with our 4-mix 
experiments and with previous findings (159). Because all of this evidence 
demonstrates that resistance to VRE is exclusively mediated by the 
microbiota, we sought to determine whether the in vivo effects observed with 
our bacterial consortia could be recapitulated ex vivo and in vitro. To this end, 
we collected fecal pellets from ampicillin-treated mice colonized with the 
different bacterial mixtures, resuspended them in PBS under anaerobic 
conditions, inoculated them with VRE and assessed VRE expansion the 
following day. Similar to our in vivo observations, we found that VRE was 
significantly inhibited in fecal samples from mice colonized with the 7- and 4-
mix while it expanded to a density of 1010 CFU/g feces in stool from mice 
colonized with P. distasonis, B. sartorii and B. producta (3-mix B); P. 
distasonis and B. sartorii (2-mix A); C. bolteae and B. producta (2-mix B) as 
well as PBS-treated animals (Figure 4.3A). In contrast to our in vivo findings, 
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fecal pellets from mice colonized with P. distasonis, B. sartorii and C. bolteae 
(3-mix A) were inhibitory to VRE.  
Similarly, incubation of fecal pellets from ampicillin-treated mice with the 
4 strains resulted in suppression of VRE growth by 4 logs, while incubation 
with P. distasonis and B. sartorii did not have any effect on VRE expansion 
(Figure 4.4B). Interestingly, introduction of C. bolteae and B. producta 
inhibited VRE albeit not as efficiently as the 4-mix, suggesting that residual 
ampicillin in the feces may suppress their activity and that both strains may be 
sufficient to prevent VRE growth (Figure 4.4B). Since a change in pH and 
competition for nutrients could explain the inhibitory effect of the 4 strains, we 
filtrated the 4-mix/fecal cultures and re-inoculated them with VRE. We found 
that VRE expanded to 1010 CFU in filtrates from fecal suspensions that had 
been incubated with either the 4 strains or PBS (Figure 4.4C). Not only do 
these observations demonstrate that nutrient limitation is not the mechanism 
Figure 4.4. Bacterial isolates suppress VRE growth ex vivo and in vitro. (A) Fecal pellets from ampicillin-
treated mice colonized with different bacterial mixtures were inoculated with VRE and incubated overnight. 
**P=0.0040, ***P=0.0007, ****P<0.0001, by the Mann-Whitney test. L.o.D. Limit of detection. (B) Fecal pellets 
from ampicillin-treated mice were inoculated with bacterial isolates from each mix in addition to VRE. VRE 
growth was assessed after 16-24 hours. **P=0.0043, ***P=0.0009, by the Mann-Whitney test. (C) Filtrates from 
fecal cultures in (B) were inoculated with  VRE an incubated overnight. (A-C) 7-mix (A. muciniphila, E. dolichum, 
unclassified Blautia, C. bolteae, B. producta, P. distasonis and B. sartorii), 4-mix (C. bolteae, B. producta, P. 
distasonis and B. sartorii), 3-mix A (C. bolteae, P. distasonis and B. sartorii), 3-mix B (B. producta, P. distasonis 
and B. sartorii), 2-mix A (C. bolteae, B. producta) and 2-mix B (P. distasonis and B. sartorii).
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by which these 4 strains exert colonization resistance but also that the factors 
critical for protection are either insoluble or short-lived.  
 
4.2.4.  C. bolteae and B. producta eliminate established VRE from the 
gastrointestinal tract 
Our in vitro findings that C. bolteae and B. producta had a significant inhibitory 
effect on VRE suggested the possibility that P. distasonis and B. sartorii, the 
other two components of the 4-mix may not be required. Members of the 
Bacteroidetes phylum, mainly Bacteroides spp., possess glycoside hydrolases 
that break down complex carbohydrates into simple sugars that serve as a 
nutrient source for other members of the community (172). Therefore, it is 
possible that in addition to their ampicillin-degrading properties, P. distasonis 
and B. sartorii may increase the nutrient availability in the gut and as a 
consequence, enhance the engraftment and growth of ampicillin-sensitive C. 
bolteae and B. producta. To address whether P. distasonis and B. sartorii 
were required solely for the degradation of ampicillin or had a more essential 
role in the protection exerted by the 4-mix, we pre-treated mice with ampicillin 
for 1 week, infected them with VRE and stopped antibiotic treatment the day of 
infection. We waited 3 days to allow VRE to colonize and ampicillin to clear 
from the gut prior to administering the first of 3 daily doses of PBS, a mixture 
of C. bolteae and B. producta or a mixture of all 4 bacteria (C. bolteae, B. 
producta, P. distasonis and B. sartorii). To determine how these two bacterial 
combinations would affect VRE colonization, we collected fecal samples 
before administration of the first dose (day 0) and on days 3, 6, 9 and 12 post 
treatment (Figure 4.5A). The purpose of this experiment was two-fold: 1) to 
determine whether the 4-mix, in addition to providing colonization resistance, 
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could clear established VRE and 2) to determine whether P. distasonis and B. 
sartorii were dispensable in the absence of antibiotic pressure. We found that 
3 days following infection (day 0), all mice were densely colonized with VRE. 
In contrast to PBS-treated animals, which remained colonized throughout the 
duration of the experiment, mice inoculated with C. bolteae and B. producta or 
the 4-mix exhibited a progressive reduction in VRE levels and were able to 
clear VRE by day 12 post treatment from the small and large intestines 
(Figure 4.5B-C), demonstrating that the same level of decolonization 
efficiency obtained with FMT (159,176) can be achieved with only two 
bacterial species.    
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Figure 4.5. Administration of C. bolteae and B. producta clears VRE colonization. (A) Model for 
adoptive transfer. * denotes fecal pellets collected at indicated time points. (B-C) VRE burden in (B) the large 
intestine at various time points post transfer and (C) small intestinal content on day 12 post suspension 
administration. L.o.D. Limit of detection. C.B., C. bolteae; B.P., B. producta; P.D., P. distasonis; B.S., B. 
sartorii.
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4.3. DISCUSSION 
Enterococci are extremely hardy organisms. They can survive for extended 
periods of time on surfaces such as doorknobs, faucets and medical 
equipment and have been shown to be tolerant to heat and alcohol-based 
solutions (232,233). The resilience and multi-drug level resistance of these 
organisms make the prevention and treatment of Enterococcus infections 
incredibly difficult. VRE bacteremia is a frequent complication in the clinic, 
particularly in patients with a deficient immune system and severe microbiota 
perturbations such as those undergoing allogeneic bone marrow 
transplantation (14,158). Once in the bloodstream, VRE can reach the heart 
and cause infective endocarditis, a condition that is potentially lethal if not 
treated in a timely manner (163). A risk factor for VRE bacteremia is 
colonization of the intestine (158). Patients that either harbor VRE in their guts 
or acquire it from the environment can become colonized if colonization 
resistance has been lost due to antibiotic treatment. Complications that 
weaken the intestinal barrier can result in translocation of VRE from the 
intestine into the blood. Therefore, efficient colonization resistance as well as 
decolonization strategies must be implemented in order to prevent VRE 
dissemination.  
Fecal microbiota transplantation (FMT) provides full recovery from 
various intestinal infections (228). However, the concern exists that 
undetectable pathogens may be transmitted from donor to recipient. This issue 
can be overcome through the use of keystone bacteria within FMT that 
mediate resistance to infection. Using the ampicillin-resistant flora (ARF) as a 
model system, we identified bacteria that correlated strongly with resistance to 
VRE. This was accomplished by diluting the colonization resistance capacity 
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of ARF to generate variation in VRE protection. Adoptive transfer of isolated 
resistance-associated strains into antibiotic-treated mice revealed that a 
bacterial cocktail comprising two species, namely Clostridium bolteae and 
Blautia producta, was sufficient to prevent VRE from colonizing the intestine 
and to eradicate it once it became established. The ampicillin susceptibility of 
C. bolteae and B. producta required the addition of the β-lactamase-producing 
strains P. distasonis and B. sartorii during antibiotic treatment. Importantly, 
colonization with these strains did not have any significant impact on VRE 
although in the ileum, the density of VRE was higher than that of control 
animals. This observation is in line with previous findings showing that 
metabolic by-products of Bacteroides spp. enhance the growth of S. 
typhimurium and C. difficile (19,183). 
Previously, we showed that the presence of bacteria belonging to the 
genus Barnesiella (S24-7) positively correlated with resistance to VRE in 
humans and in mice (14). Consistent with these findings, we identified 
Barnesiella OTUs in our model that were significantly associated with VRE 
protection. However, none of our isolated strains matched the sequence of 
those OTUs. Although we were able to restore colonization resistance with 
bacterial mixtures that did not contain Barnesiella, it is possible that specific 
Barnesiella strains may be inhibitory as part of other bacterial combinations. 
Alternatively, the presence of Barnesiella may indicate an association with a 
healthy microbiota capable of providing colonization resistance rather than a 
direct association with VRE protection.   
Supporting the notion that bacteria work in collaboration and not in 
isolation, we showed that neither C. bolteae nor B. producta provided 
protection against VRE when administered separately. This observation 
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suggests that metabolic by-products of C. bolteae or B. producta may serve as 
substrates for the opposite bacterium which is then equipped to produce VRE-
inhibitory factors. On the other hand, both organisms may have the capacity to 
inhibit VRE but their interaction is required for this effect. Another possibility is 
that the localization of these bacteria within the intestine may impact their 
behavior. For instance, whereas mice colonized with C. bolteae, P. distasonis 
and B. sartorii were susceptible to colonization, their fecal pellets inhibited 
VRE growth ex vivo, suggesting that pathways involved in colonization 
resistance are functional in these animals. One explanation for this 
discrepancy is compartmentalization of protective strains and consequently, 
different mechanisms of resistance. While C. bolteae seems to be the major 
player in the large intestine, it is possible that B. producta alone or together 
with C. bolteae mediates resistance to VRE in the small intestine. Supporting 
this hypothesis, we found that B. producta represented 65-98% of the total 
bacterial population in the small intestinal microbiota of mice colonized with all 
4 strains (B. producta, C. bolteae, P. distasonis and B. sartorii). Therefore, in 
the presence of C. bolteae but absence of B. producta, VRE may colonize the 
small intestine and lead to continued VRE seeding in the colon, an event that 
may override the inhibitory effects of C. bolteae. On the other hand, the lack of 
in vivo and ex vivo protection following treatment with B. producta in the 
absence of C. bolteae suggests that C. bolteae may aid B. producta to engraft 
and expand within the intestine in order to be effective against VRE.  
Importantly, we showed that the mechanism of colonization resistance 
exerted by C. bolteae and B. producta do not involve nutrient depletion and 
changes in environmental pH. These observations point in the direction of 
bacterial metabolites generated through fermentation, such as short chain fatty 
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acids (SCFAs), and conversion of host-derived bile salts. SCFAs are the end 
products of bacterial fermentation by intestinal microbiota. Acetate, a major 
constituent of intestinal SCFA, was shown to be protective against 
enterohaemmorhagic E.coli through reinforcement of the intestinal barrier (20). 
Importantly, C. bolteae and B. producta strains isolated from human feces 
were shown to produce large amounts of acetate in vitro (115). Aside from 
SCFAs, the conversion of primary into secondary bile salts by another 
member of the Clostridia cluster XIVa, Clostridium scindens, has recently been 
implicated in protection against C. difficile (145). In addition to SCFAs and bile 
salts, bacteriocin-producing bacteria have been shown to outcompete 
Enterococcus faecalis in vivo. We are currently investigating these possibilities 
in our laboratory.  
Lastly, we demonstrated that the rate of VRE clearance by C. bolteae 
and B. producta mimics that obtained with FMT, indicating that a feat as great 
as colonization resistance, normally afforded by a complex and diverse 
microbiota, can be mediated by at least two bacterial species.  Altogether, our 
findings provide empirical support for the development of novel probiotic 
therapies using well-characterized commensal bacteria to target intestinal 
infection, a clinical application that provides a promising and safer alternative 
to FMT without sacrificing efficiency.  
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4.4. MATERIALS AND METHODS 
 
4.4.1.  Mice and infections. 6-8 week old female mice from Jackson 
Laboratories were treated with 0.5g/L ampicillin (Fisher) in their drinking water 
made fresh every 4 days. For VRE infection, 5x104 CFU of VRE (ATCC 
700221) were administered to mice by oral gavage. Mice were single-housed 
at the time of infection and kept on ampicillin until the end of the experiment 
unless otherwise noted. Tenfold dilutions of pre-weighed intestinal samples 
resuspendend in PBS were plated on Difco Enterococcosel agar 
(supplemented with 8 μg/ml vancomycin; Novaplus and 100 μg/ml 
streptomycin; Fisher). 
 
4.4.2.  DNA extraction, multiparallel sequencing and sequence analysis. 
DNA from intestinal samples was extracted using the phenol-chloroform 
extraction method (14). The V4-V5 region of the 16S rRNA gene was amplified 
and sequenced with the Illumina Miseq platform as described previously (145). 
Sequences were analyzed using version 1.33.3 of the MOTHUR pipeline (7) 
as described in Buffie et al., 2015. Sequences with distance-based similarity of 
at least 97% were grouped into OTUs. A modified Greengenes reference 
database (188) was used for OTU classification. The Inverse Simpson index 
was used to compute sample biodiversity at the OTU-level. 
 
4.4.3.  Bacterial culture and isolation. To isolate bacteria from ARF, fecal 
samples from MyD88-/- mice were collected, transferred immediately to an 
anaerobic chamber, resuspended in 1 ml of sterile pre-reduced PBS. Samples 
were serially diluted and 100 µl from the 10-5 and 10-6 dilutions were plated on 
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non-selective Columbia agar supplemented with 5% sheep blood (BD 
Biosciences) and at 37oC anaerobically for 3-5 days. For inocula preparation 
of dilution cultures, bacteria were harvested and resuspended in PBS and 
glycerol at a final concentration of 15% glycerol. To isolate bacteria, colonies 
were picked from 10-5 plates and streaked onto fresh agar to ensure purity. 
Isolated strains were resuspended in PBS and glycerol (15%) and stored at -
80oC. The 16S rRNA gene was amplified by colony PCR using primers 8F (5’-
AGAGTTTGATCCTGGCTCAG-3’) and 1492R (5’ –GGTTACCTTGTTACGAC 
TT-3’). The resulting PCR product was Sanger sequenced with primers 
spanning the full 16S gene (8F and 1492R) as well as primers specific to the 
V4-V5 region (517F, 5’-GCCAGCAGCCGCGGTAA-3’) and classified using 
BLAST. For colonization experiments, resistance-associated bacteria were 
cultured on Columbia blood agar plates for 3 days under anaerobic conditions, 
scraped off and mixed in a 1:1 ratio (107-108 CFU per isolate) in PBS and 
glycerol (15%). All bacterial cultures were orally gavaged into mice in a 200 µl 
volume. 
 
4.4.4.  Ex vivo and in vitro VRE suppression assay. For ex vivo assays, 
fecal samples from C57BL/6 ampicillin-treated colonized with different 
bacterial mixtures were transferred to an anaerobic chamber and resuspended 
in pre-reduced PBS at a concentration of 25 mg/ml. For in vitro assays, 107-
108 CFU of each resistance-associated strain were added to fecal pellets from 
antibiotic-treated mice and incubated overnight prior to VRE inoculation. VRE 
(5x103 CFU) or PBS was added to each sample and incubated at 37 oC 
anaerobically. VRE growth was assessed 16-24 hours later by plating on 
selective media. Fecal filtrates were obtained by filtering overnight fecal 
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cultures of VRE grown in the presence or absence of resistance-associated 
strains over a 0.22 µm filter prior to VRE re-inoculation. For antibiotic 
treatment, fecal pellets from ampicillin mice colonized with ARF or not were 
resuspended in reduced PBS and metronidazole (Sigma-Aldrich), gentamicin 
(Fisher) or streptomycin (Fisher) at 0.5 mg/ml was added at the time of VRE 
inoculation. 
 
4.4.5.  Statistics. Statistical analyses were performed using R Statistical 
Language (version 3.1.1) and Graph-Pad Prism (version 6.0). Two-tailed 
unpaired Student’s t test was used to determine if VRE levels were statistically 
significant among different groups. The Mann-Whitney nonparametric test was 
to determine statistical significance in biodiversity scores. Spearman’s rank 
correlation test (two-tailed) was used to determine statistical correlations 
between two variables. The Benjamini-Hochberg method was applied to 
control for false discovery rate. For the Student’s t test, Mann-Whitney test and 
Spearman’s correlation test, P values < 0.05 were considered significant. 
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CHAPTER 5 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
One of the most critical roles of the microbiota is to prevent pathogen 
expansion. Treatment with antimicrobial agents kills a good fraction of the 
intestinal bacterial community and renders the host susceptible to colonization 
by multidrug-resistant organisms including VRE and K. pneumoniae. The work 
presented here outlines different aspects of host-bacterial and bacterial-
bacterial interactions with a focus on colonization resistance. 
In Chapter 2 we showed that VRE and K. pneumoniae expand to 
similar densities in the intestine during co-colonization and induce different 
levels of mucus production. Given the extent to which these organisms 
colonize together with the limited amount of resources in the intestine as a 
result of antibiotic-mediated depletion of the microbiota, we had originally 
hypothesized that they might compete with each other in the gut. However, 
their close proximity to each other suggests that they most likely interact 
despite not interfering with each other’s growth. How VRE and K. pneumoniae 
adapt to the intestinal environment when alone or in the presence of the other 
is currently under investigation.  
Colonization by these highly antibiotic-resistant pathogens is known to 
precede bacteremia in patients undergoing harsh treatments such as 
chemotherapy. Therefore, novel therapies to prevent and/or eliminate 
colonization are of great need in the clinic. One approach is the identification 
of bacteria that directly mediate colonization resistance and the underlying 
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mechanisms by which they do so. The work presented in Chapters 3 and 4 of 
this dissertation provides evidence of a causal relationship between specific 
bacterial strains and colonization resistance against VRE. In Chapter 3 we 
describe the development of population-wide antibiotic resistance in the 
mammalian gut as a result of long-term antibiotic treatment. Within this 
complex bacterial community, we identified a combination of two strains, C. 
bolteae and B. producta, that together were able to completely restore 
protection against VRE (Chapter 4). Importantly, both of these organisms are 
components of a healthy microbiota in humans (23). Whether human-derived 
C. bolteae and B. producta exert the same protective roles as their murine 
counterparts remains to be explored.    
An important aspect of using a defined set of strains as therapy is 
pathogen specificity. Despite the remarkable ability to target VRE, C. bolteae 
and B. producta do not provide any protection against multidrug-resistant K. 
pneumoniae and E.coli (data not shown). Therefore, the players and rules 
involved in colonization resistance against different bacterial groups are not 
the same. Since Enterococci and Enterobactericeae can co-colonize the 
intestine, an ideal treatment would involve the administration of several 
commensal bacteria that can target multiple pathogens at one. The purpose of 
these studies is to enhance our understanding of how intestinal bacterial 
populations behave and how they impact resistance or susceptibility to VRE, 
making defined bacteriotherapy against VRE and other intestinal pathogens a 
real possibility.  
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APPENDIX 1 
 
SUPPLEMENTARY FIGURES FOR CHAPTER 2 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2.1. Ampicillin treatment leads to VRE and K. pneumoniae 
expansion in the intestine.
Untreated mice (A) and mice treated with ampicillin in the drinking water for 1 week (B) were 
colonized with 108 CFU of VRE or K. pneumoniae and bacterial burden was quantified in the 
feces on days 1, 3 and 7 post infection. Ampicillin-treated animals were kept on ampicillin for 
the duration of the experiment. L.O.D., limit of detection.  
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Supplementary Figure 2.2. Visualization of morphologically distinct intestinal bacteria by 
FISH
Colon sections from untreated mice (A) and mice treated with ampicillin in the drinking water for 3 
weeks (B) were hybridized with a universal bacterial probe directed against the 16S rRNA gene 
and counterstained with Hoechst dye to visualize nuclei. Scale bars, 10 μm. Inset, 63X oil 
objective plus 4X digital zoom. Images are representative of 5 mice per group.
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APPENDIX 2 
 
SUPPLEMENTARY FIGURES FOR CHAPTER 3 
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APPENDIX 3 
 
SUPPLEMENTARY FIGURES FOR CHAPTER 4 
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Supplementary Figure 4.1. Defined bacterial consortia restore colonization resistance against VRE in 
the small intestine. (A-C) Ampicillin-treated mice were inoculated with PBS or combinations of 5 bacteria 
isolated from ARF cultures on three consecutive days beginning the day following antibiotic initiation. Mice 
were infected with VRE the day after the last PBS/bacterial dose. Data corresponds to d5 p.i. Ampicillin 
treatment was continued throughout. (n=3-6 mice per group). L.o.D., limit of detection. (B) Ileal microbiota 
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PBS, 5-mix (A. muciniphila, C. bolteae, B. producta, P. distasonis and B. sartorii), 4-mix (C. bolteae, B. 
producta, P. distasonis and B. sartorii), 3-mix A (C. bolteae, P. distasonis and B. sartorii), 3-mix B (B. 
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sartorii).
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Supplementary Figure 4.2. Live anaerobic bacteria suppress VRE expansion ex vivo.  (A-B) Fecal 
pellets from (A) ampicillin-treated mice and (B) ampicillin-treated mice colonized with ARF were treated with 
gentamicin, streptomycin, metronidazole or no antibiotics (-) and inoculated with VRE. (C) Fecal samples 
from ARF-colonized ampicillin-treated mice were incubated at the indicated temperatures for 15 min prior to 
VRE inoculation. (A-C) VRE expansion was measured 16-24 hours later. L.o.D., limit of detection.
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